Form 8-K

8-K — Change Agents Corporation.

Accession: 0001213900-26-099714

Filed: 2026-09-14

Period: 2026-09-08

CIK: 0001630212

SIC: 7371 (SERVICES-COMPUTER PROGRAMMING SERVICES)

Item: Entry into a Material Definitive Agreement

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Unregistered Sales of Equity Securities

Item: Financial Statements and Exhibits

Documents

8-K — ea030536101-8k_change.htm (Primary)

EX-4.1 — FORM OF SEPTEMBER 2026 OID NOTE (ea030536101ex4-1.htm)

EX-4.2 — FORM OF SEPTEMBER 2026 PRE-FUNDED WARRANT (ea030536101ex4-2.htm)

EX-4.3 — FORM OF WAIVER PRE-FUNDED WARRANT (ea030536101ex4-3.htm)

EX-10.1 — FORM OF NOTE PURCHASE AGREEMENT (ea030536101ex10-1.htm)

EX-10.2 — SECOND AMENDMENT TO EQUITY PURCHASE AGREEMENT DATED SEPTEMBER 9, 2026 (ea030536101ex10-2.htm)

EX-10.3 — FORM OF SEPTEMBER 2026 WAIVER (ea030536101ex10-3.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea030536101-8k_change.htm · Sequence: 1

false

0001630212

2026-09-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

September 8, 2026

Change Agents Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-38728

47-1685128

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I. R. S. Employer

Identification No.)

4400 Route 9 South, Suite 3100

Freehold, NJ 07728

(Address of principal executive offices, including

ZIP code)

(732) 780-4400

(Registrant’s telephone number, including

area code)

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.0001 par value

CHGA

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

September 2026 Original

Issue Discount Note and Pre-Funded Warrant

On September 8, 2026,

the Company issued promissory notes to certain accredited investors in the aggregate principal amount of $280,000 (inclusive of a $30,000

original issuance discount) (the “September 2026 OID Notes”) for gross proceeds of $250,000. The Company the net proceeds

of the September 2026 OID Notes to repay (i) $19,710under that certain 7% promissory note in the original principal amount of $233,910

issued to Vanquish Funding Group Inc. and (ii) $19,710 under those certain 18.75 % notes issued in June 2025. The remaining net proceeds

will be used for working capital and general corporate purposes. In addition, the Company issued pre-funded warrants (“September

2026 Pre-Funded Warrants”) to purchase 1,000,000 shares of its common stock (“September 2026 Pre-Funded Warrant Shares”)

as an inducement for investors to purchase the September 2026 OID Notes.

The September 2026 OID

Notes mature on April 8, 2027 and accrues interest at a rate of 7% per annum which increases to 15% (or the maximum amount permitted by

law) during the existence of an event of default. The September 2026 OID Notes may be prepaid at any time at 105% of the original principal

amount. The September 2026 OID Notes contain negative covenants, including restrictions on additional indebtedness while the notes are

outstanding.

The Company granted the

investors in the Note Purchase Agreement a “most-favored nations” provision with respect to the issuance of any debt that

is not convertible into common stock of the Company (or amends any non-convertible debt that was issued before the Issue Date).

The September 2026 Pre-Funded

Warrants are immediately exercisable and may be exercised at a nominal exercise price of $0.0001 per share of Common Stock at any time

until all of the September 2026 Pre-Funded Warrants are exercised in full; provided, however, that until the Company has obtained stockholder

approval for issuance of the September 2026 Pre-Funded Warrant Shares, the Company shall not issue a number of September 2026 Pre-Funded

Warrant Shares, which when aggregated with all other securities that are required to be aggregated for purposes of Nasdaq Listing Rule

5635(d), would exceed 19.99% of the shares of Common Stock outstanding as of the date of definitive agreement with respect to the first

of such aggregated transactions A holder may not exercise any portion of the September 2026 Pre-Funded Warrants to the extent a purchaser

would own more than 4.99% of the outstanding Common Stock immediately after exercise. A holder may increase or decrease this percentage

with respect to September 2026 Pre-Funded Warrants to a percentage not in excess of 9.99%, except that any such increase shall require

at least 61 days’ prior notice to the Company.

The foregoing descriptions of each of the Note Purchase Agreement,

September 2026 OID Notes and the September 2026 Pre-Funded Warrants does not purport to be complete and are qualified in their entirety

by reference to the full text of such agreements and instruments, copies of which are filed as Exhibits 10.1, 4.1 and 4.2, respectively,

to this Current Report on Form 8-K and are incorporated herein by reference.

Amendment

to Equity Purchase Agreement for Equity Line

On September 9, 2026, Change Agents Corporation (the “Company”)

entered into a Second Amendment (the “Second Amendment”) to that certain Equity Purchase Agreement dated July 22, 2026 as

amended by that First Amendment (the “First Amendment”) to Equity Purchase Agreement dated August 21, 2026 (as amended by

the First Amendment and the Second Amendment, the “Purchase Agreement”), between the Company and Hudson Global Ventures, LLC,

a Nevada limited liability company (the “Investor”). The Amendment amended the terms of the original Purchase Agreement as

amended by the First Amendment pursuant to which the Company may, upon the terms and subject to the conditions set forth therein, require

the Investor to purchase shares of the Company’s common stock, par value $0.0001 per shares (“Common Stock”) having

an aggregate purchase price of up to $10,000,000 to (a) reduce the purchase price for shares sold to the Investor under the Purchase Agreement

to $2.00 per share and to amend and restate the Applicable Trading Amount for each Put (i.e. the amount that the Company can require the

investor to purchase) as follows:

(a)

$15,000.00 if (i) the VWAP of the Common Stock during the period beginning at the start of regular trading hours” as defined in Rule 600(b)(88) of Regulation NMS promulgated under the federal securities laws on the Put Date and continuing through the time of the delivery of the Put Notice to Investor is greater than $2.50, and (ii) the total trading volume of the Company’s Common Stock on the Principal Market on the Put Date prior to the delivery of the Put Notice to Investor exceeds 100,000 shares; or

-1-

(b)

$15,000.00 if the lowest closing price of the Common Stock during the two (2) Trading Days immediately preceding the respective Put Date is greater than $3.00 but less than or equal to $3.50; or

(c)

$25,000.00 if the lowest closing price of the Common Stock during the two (2) Trading Days immediately preceding the respective Put Date is greater than $3.50 but less than or equal to $4.00; or

(d)

$100,000.00 if the lowest closing price of the Common Stock during the two (2) Trading Days immediately preceding the respective Put Date is greater than $4.00 but less than or equal to $5.00; or

(e)

$200,000.00 if the lowest closing price of the Common Stock during the two (2) Trading Days immediately preceding the respective Put Date is greater than $5.00 but less than or equal to $6.50; or

(f)

$350,000.00 if the lowest closing price of the Common Stock during the two (2) Trading Days immediately preceding the respective Put Date is greater than $6.50 but less than or equal to $9.00; or

(g)

$450,000.00 if the lowest closing price of the Common Stock during the two (2) Trading Days immediately preceding the respective Put Date is greater than $9.00 but less than or equal to $15.00; or

(h)

$500,000.00 if the lowest closing price of the Common Stock during the two (2) Trading Days immediately preceding the respective Put Date is greater than $15.00.

For the avoidance

of doubt, each of the closing prices as well as the number of shares identified above in this definition of Applicable Trading Amount

are subject to adjustment for any stock dividend, stock split, stock combination, rights offerings, reclassification or similar transaction

that proportionately decreases or increases the number of outstanding Common Stock. Notwithstanding the foregoing, if the parameters in

any of the subsections (b) through (h) of the definition of Applicable Trading Amount are satisfied on the respective Put Date, then subsection

(a) of the definition of Applicable Trading Amount shall not apply on the respective Put Date.

The Amendment also included

an Exchange Cap whereby until the Company obtains stockholder approval for the transactions contemplated by the Equity Purchase Agreement,

as amended by the First Amendment,, the Company shall not issue an aggregate amount of Put Shares under the Agreement, which when aggregated

with all other securities that are required to be aggregated for purposes of Nasdaq Listing Rule 5635(d), would exceed 19.99% of the shares

of Common Stock outstanding as of the date of definitive agreement with respect to the first of such aggregated transactions.

The foregoing description

of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy

of which is filed as Exhibits 10.1 to this Current Report on Form 8-K and are incorporated herein by reference.

Waivers and Pre-Funded

Warrants

On each of September 10, 2026 and September 14, 2026, the Company entered

into certain waivers (the “September 2026 Waiver”) with each of Dune Equity Holdings, LLC (“Dune”) and FirstFire

Opportunities Fund, LLC (“Firstfire”) of provisions under outstanding notes held by them to allow for the Company to issue

the September 2026 OID Notes. In consideration of these September 2026 Waivers, the Company agreed to issue each of Dune and FirstFire

pre-funded warrants (collectively, the “Waiver Pre-Funded Warrants”) to purchase 50,000 and 34, 000 shares of Common Stock,

respectively (collectively, the “Waiver Pre-Funded Warrant Shares”). The Waiver Pre-Funded Warrants are immediately exercisable

and may be exercised at a nominal exercise price of $0.0001 per share of Common Stock at any time until all of the Waiver Pre-Funded Warrants

are exercised in full; provided, however, that until the Company has obtained stockholder approval for issuance of the Waiver Pre-Funded

Warrant Shares, the Company shall not issue a number of Waiver Pre-Funded Warrant Shares, which when aggregated with all other securities

that are required to be aggregated for purposes of Nasdaq Listing Rule 5635(d), would exceed 19.99% of the shares of Common Stock outstanding

as of the date of definitive agreement with respect to the first of such aggregated transactions A holder may not exercise any portion

of the Waiver Pre-Funded Warrants to the extent the Purchaser would own more than 4.99% of the outstanding Common Stock immediately after

exercise. A holder may increase or decrease this percentage with respect to September 2026 Pre-Funded Warrants to a percentage not in

excess of 9.99%, except that any such increase shall require at least 61 days’ prior notice to the Company. In addition, the Company

shall not issue a number of Common Stock pursuant to the exercise of this Warrant, which when aggregated with all other securities that

are required to be aggregated for purposes of Nasdaq Listing Rule 5635(d), would exceed 19.99% of the shares of Common Stock outstanding

as of the date of definitive agreement with respect to the first of such aggregated transactions, unless the Company has obtained the

Stockholder Approval The Waiver Pre-Funded Warrants also provide that if the Company fails to procure stockholder approval for issuance

of the Waiver Pre-Funded Warrant Share on or before the date which is 90-days after issuance of the Waiver Pre-Funded Warrants, then the

holders of such warrants will have the right to require the Company to pay a buyout fee redeem the warrants in the amount of $125,000

for Dune and $75,000 for FirstFire.

-2-

The foregoing description of each of the September 2026 Waivers and

the Waiver Pre-Funded Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of the September

2026 Waivers and the Waiver Pre-Funded Warrants , copies of which are filed as Exhibits 10.3 and 4.3 to this Current Report on Form 8-K

and are incorporated herein by reference.

Item 2.03 Creation

of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth

under Item 1.01 of this Current Report on Form 8-K relating to the September 2026 OID Notes is incorporated by reference into this Item

2.03.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 of this Current Report on

Form 8-K relating to the September 2026 Pre-Funded Warrant, the shares of Common Stock issuable upon exercise of the September 2026 Pre-Funded

Warrant, the Purchase Agreement and the September 2026 Pre-Funded Warrant Shares the Purchase Agreement and the Shares of Common Stock

issuable thereunder (the “ELOC Shares”) and the Waiver Pre-Funded Warrants and the Waiver Pre-Funded Warrant Shares is incorporated

by reference into this Item 3.02. The September 2026 Pre-Funded Warrant, the September 2026 Pre-Funded Warrant Shares, the ELOC Shares,

the Waiver Pre-Funded Warrants and the Waiver Pre-Funded Warrant Shares have not been registered under the Securities Act of 1933, as

amended (the “Securities Act”), or any state securities laws and were offered and sold, or will be issued, in reliance upon

exemptions from the registration requirements of the Securities Act, including Section 4(a)(2) of the Securities Act and/or Rule 506(b)

of Regulation D promulgated thereunder, and applicable state securities laws.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The exhibit listed in the following Exhibit Index

is filed as part of this Current Report on Form 8-K.

Exhibit No.

Description of Exhibit

4.1

Form of September 2026 OID Note

4.2

Form of September 2026 Pre-Funded Warrant

4.3

Form of Waiver Pre-Funded Warrant

10.1*

Form of Note Purchase Agreement

10.2

Second Amendment to Equity Purchase Agreement dated September 9, 2026

10.3

Form of September 2026 Waiver

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation

S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange

Commission upon request.

-3-

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Date: September 14, 2026

Change Agents Corporation

/s/ Sam Knipper

Sam Knipper

Chief Financial Officer

-4-

EX-4.1 — FORM OF SEPTEMBER 2026 OID NOTE

EX-4.1

Filename: ea030536101ex4-1.htm · Sequence: 2

Exhibit 4.1

THIS SECURITY HAS NOT BEEN REGISTERED WITH

THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER

THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT

TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT

TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL

OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY

MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITY.

Original Issue Date: September _, 2026

$_____ Principal

$_____ Purchase Price

$___ Original Issue Discount

original

issue discount

PROMISSORY

NOTE

THIS ORIGINAL ISSUE DISCOUNT

PROMISSORY NOTE is duly authorized and validly issued at an original issue discount by CHANGE AGENTS CORPORATION, a Delaware corporation

(the “Company”) (the “Note”).

FOR VALUE RECEIVED, the Company

promises to pay to ______________ – C/M Capital Series (the “Holder”), the principal sum of $_____ on the date

that is the nine month anniversary of the Original Issue Date (the “Maturity Date”) or such earlier date as

this Note is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate and then outstanding

principal amount of this Note in accordance with the provisions hereof. This Note is one of a series of Notes issued pursuant to the Purchase

Agreement in the aggregate principal amount of $280,000. This Note is subject to the following additional provisions:

Section 1. Definitions.

For the purposes hereof, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement

and (b) the following words and phrases shall have the following meanings:

“Bankruptcy Event”

means any of the following events: (a) the Company or any Subsidiary thereof commences a case or other proceeding under any bankruptcy,

reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction

relating to the Company or any Subsidiary thereof, (b) there is commenced against the Company or any Subsidiary thereof any such case

or proceeding that is not dismissed within 30 days after commencement, (c) the Company or any Subsidiary thereof is adjudicated insolvent

or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Subsidiary

thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or

stayed within 30 calendar days after such appointment, (e) the Company or any Subsidiary thereof makes a general assignment for the benefit

of creditors, (f) the Company or any Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment

or restructuring of its debts or (g) the Company or any Subsidiary thereof, by any act or failure to act, expressly indicates its consent

to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the

foregoing.

“Change of Control Transaction”

means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual or legal entity or “group”

(as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership

of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities of the Company, (b) the Company

merges into or consolidates with any other Person, or any Person merges into or consolidates with the Company and, after giving effect

to such transaction, the shareholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power

of the Company or the successor entity of such transaction, (c) the Company sells or transfers all or substantially all of its assets

to another Person, (d) a replacement at one time or within a three year period of more than one-half of the members of the Board of Directors

which is not approved by a majority of those individuals who are members of the Board of Directors on the Original Issue Date (or by those

individuals who are serving as members of the Board of Directors on any date whose nomination to the Board of Directors was approved by

a majority of the members of the Board of Directors who are members on the date hereof), or (e) the execution by the Company of an agreement

to which the Company is a party or by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.

“Common Stock”

shall have the meaning ascribed to “Common Stock” in the Purchase Agreement.

“Common Stock Equivalents”

shall have the meaning ascribed to “Common Stock Equivalent” in the Purchase Agreement.

“Default Interest Rate”

shall have the meaning set forth in Section 2(a).

“Event of Default”

shall have the meaning set forth in Section 5(a).

“Exchange Act”

shall have the meaning set forth in the Purchase Agreement.

“Indebtedness”

shall have the meaning set forth in the Purchase Agreement.

“Liens” means

any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority

or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including

any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property, and

any financing lease having substantially the same economic effect as any of the foregoing).

“Mandatory Default Amount”

means the sum of 125% of the aggregate of (i) the outstanding principal amount of this Note and the accrued and unpaid interest

thereon, including default interest, and (ii) all other amounts, costs, expenses and liquidated damages due in respect of this Note.

“Note Register”

shall have the meaning set forth in Section 3(c).

“Original Issue Date”

means the date of the first issuance of this Note, regardless of any transfers of this Note and regardless of the number of instruments

which may be issued to evidence this Note.

“Permitted Indebtedness”

means ((i) trade payables incurred in the ordinary course of business consistent with past practice; (ii) Indebtedness existing as of

the applicable Closing Date and disclosed on Schedule 5(e) to the Purchase Agreement; (iii) equipment financing and capital lease obligations

not exceeding $100,000 in the aggregate at any time outstanding; (iv) Indebtedness in an amount of up to $250,000 and (v) any Indebtedness

issued to any Holder (or its designees).

“Permitted Lien”

means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental charges or levies

not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith and by appropriate

proceedings for which adequate reserves (in the good faith judgment of the management of the Company) have been established in accordance

with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Company’s business, such as carriers’,

warehousemen’s and mechanics’ Liens, statutory landlords’ Liens, and other similar Liens arising in the ordinary course

of the Company’s business, and which (x) do not individually or in the aggregate materially detract from the value of such property

or assets or materially impair the use thereof in the operation of the business of the Company and its consolidated Subsidiaries or (y)

are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing for the foreseeable future

the forfeiture or sale of the property or asset subject to such Lien, (c) Liens incurred in connection with Permitted Indebtedness under

clauses (a) through (d) thereunder.

“Person” shall

have the meaning set forth in the Purchase Agreement.

“Purchase Agreement”

means the Note Purchase Agreement, dated as of the date hereof, between the Company and the Purchasers, as amended, modified or supplemented

from time to time in accordance with its terms.

“SEC” means the

Securities and Exchange Commission.

“Securities Act”

means the Securities Act of 1933, and the rules and regulations promulgated thereunder.

“VWAP” has the

meaning ascribed to it in the Purchase Agreement.

Section 2. Interest/Repayment.

(a) Interest. Interest

shall accrue to the Holder on the aggregate then outstanding principal amount of this Note at the rate of 7% per annum,

calculated on the basis of a 360-day year and shall accrue daily commencing on the Original Issue Date until payment in full of the outstanding

principal, together with all accrued and unpaid interest, liquidated damages and other amounts which may become due hereunder, has been

made. During the existence of an Event of Default, interest shall accrue at the lesser of (i) the rate of 15% per annum,

or (ii) the maximum amount permitted by law (the lesser of clause (i) or (ii), the “Default Interest Rate”). Interest shall

be due on the first Trading Day of each calendar month during the existence of an Event of Default. Once an Event of Default is cured,

the interest rate shall return to 7%. Absent an Event of Default, all accrued and unpaid Interest shall be payable on the

Maturity Date.

(b) Prepayment. Before

the Maturity Date, all amounts due and owing hereunder, including all accrued and unpaid interest, may be repaid by the Company upon five

days’ prior written notice to the Holder in an amount equal to 105% of all amounts due and owing hereunder, including all accrued

and unpaid interest, on such repayment date.

Section 3. Registration of Transfers

and Exchanges.

(a) Different Denominations.

This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the

Holder surrendering the same. No service charge or other fees will be payable for such registration of transfer or exchange.

(b) Investor Representations.

This Note has been issued subject to certain investment representations of the original Holder of this Note set forth in the Purchase

Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal and state securities

laws and regulations.

Register. Prior to due presentment for transfer to the Company of this Note, the Company and any agent of the Company may treat the

Person in whose name this Note is duly registered on the Note Register as the owner hereof for the purpose of receiving payment as herein

provided and for all other purposes, whether or not this Note is overdue, and neither the Company nor any such agent shall be affected

by notice to the contrary.

Section 4. Negative Covenants.

As long as any portion of this Note remains outstanding, the Company shall not, and shall not permit any of the Subsidiaries to, directly

or indirectly, take any of the following actions without the prior written consent of Holders holding a majority in principal amount of

all Notes then outstanding; provided, however, that the prior written consent of the Holder of this Note shall also be required for any

action described in clause (b) that materially and adversely affects the rights of the Holder of this Note or any action described in

clause (d) that affects the Company’s payment obligations to the Holder of this Note:

(a) other than Permitted Indebtedness

and Permitted Liens, (i) incur, assume, guarantee or suffer to exist any indebtedness for borrowed money, or (ii) create, incur or suffer

to exist any Liens, in each case on or with respect to any of its property or assets now owned or hereafter acquired;

(b) amend its charter documents,

including its certificate of incorporation and bylaws, in any manner that materially and adversely affects any rights of the Holder of

this Note (stock splits and increases in authorized Common Stock excluded), or issue equity securities with such effect;

acquire more than a de minimis number of shares of its Common Stock or Common Stock Equivalents;

(d) repay any Indebtedness

other than this Note or Permitted Indebtedness, if at such time or after giving effect to such payment any Event of Default exists or

the Company cannot satisfy its obligations to the Holder of this Note;

(e) pay cash dividends or

distributions on any equity securities of the Company;

(f) enter into any transaction

with any Affiliate that would require public disclosure under the Securities Act or Exchange Act, unless on arm’s-length terms and

approved by a majority of disinterested directors; or

(g) enter into any agreement

with respect to any of the foregoing.

Section 5. Events of Default.

(a) “Event of

Default” means the occurrence of any one or more of the following events, but only upon delivery by the Holder of this Note

to the Company of written notice declaring such event to constitute an Event of Default (a “Default Declaration”) (and regardless

of whether voluntary or involuntary, or effected by operation of law or pursuant to any judgment, decree or order of any court or governmental

body):

(i) any default in the payment

of (A) principal or interest under this Note or any other Indebtedness, or (B) late fees, liquidated damages or other amounts owing to

the Holder of this Note, in each case as and when due and payable (whether on the Maturity Date, by acceleration or otherwise); provided

that, solely with respect to clause (B), no Event of Default shall occur if such default is cured within five Trading Days;

(ii) the Company fails to observe

or perform any covenant or agreement contained in this Note or any Transaction Document (other than payment obligations covered by clause

(i)), and such failure continues uncured for 10 Trading Days after the earlier of (A) written notice from the Holder of this Note or (B)

the Company becoming aware of such failure;

(iii) a default or event

of default occurs under any material agreement, lease, document or instrument to which the Company or any Subsidiary is a party (other

than the Transaction Documents, which are covered by clause (ii)), and such default continues beyond any applicable cure period;

(iv) any representation or warranty

made in this Note, any Transaction Document, or any report, financial statement or certificate delivered to the Holder of this Note is

untrue or incorrect in any material respect as of the date made, and such breach is not cured (if curable) within 10 Trading Days after

the earlier of (A) written notice from the Holder of this Note or (B) the Company becoming aware of such breach;

(v) the Company or any Subsidiary

becomes subject to a Bankruptcy Event;

(vi) any levy, seizure, attachment,

or uninsured loss or damage affecting property of the Company or any Subsidiary with an aggregate fair value or repair cost exceeding

$100,000, which is not set aside, bonded or discharged within 10 days;

(vii) any monetary judgment,

writ or similar final process is entered against the Company, any Subsidiary or their property for more than $100,000, and remains unvacated,

unbonded or unstayed for 10 days;

(viii) a material adverse effect

occurs with respect to the Company or any Subsidiary;

(ix) any provision of any Transaction

Document ceases to be valid, binding or enforceable (other than pursuant to its express terms), or the Company or any Subsidiary contests,

or commences proceedings to establish the invalidity or unenforceability of, or denies in writing any liability under, any Transaction

Document;

(x) the Company fails to use

the net proceeds in accordance with the Purchase Agreement;

(xi) the Common Stock is suspended

from trading by the SEC, or is not listed or quoted on a Trading Market for 10 Trading Days after notice from the Holder of this Note,

or transfers of Common Stock through the Depository Trust Company System become unavailable or subject to a “chill”;

(xii) the Company becomes a

party to any Change of Control Transaction or agrees to sell or dispose of all or more than 50% of its assets (whether or not constituting

a Change of Control Transaction) provided, that it is understood and agreed to conversion of the Company’s Series E Non-Voting Convertible

Preferred Stock issued to holders of RPM Interactive, Inc. pursuant to the merger completed in December 2025 shall not constitute a Change

of Control Transact;

(xiii) the Company fails to

deliver any shares or securities required under the Transaction Documents by the second Trading Day after receipt of notice (unless caused

by the action or inaction of the Holder of this Note), or announces an intention not to honor such delivery obligations;

(xiv) the Company fails to comply

in any material respect with Exchange Act reporting requirements (including becoming delinquent in any filing, taking into account any

extension under Rule 12b-25), or ceases to be subject to Exchange Act reporting requirements;

(xv) the Company incurs, assumes,

guarantees or otherwise becomes liable for any Indebtedness other than Permitted Indebtedness;

(xvi) the Company makes a false

or inaccurate certification (including any deemed certification) as to whether any Event of Default has occurred;

(xvii) a Lien other than a Permitted

Lien is imposed on assets of the Company or any Subsidiary and is not dissolved within 10 calendar days;

(xviii) the Company fails to

deliver the original Note to the Holder of this Note within five Trading Days of the Closing;

(xix) the Company provides material

non-public information to the Holder of this Note without the prior written consent of the Holder of this Note;

(xx) the Company restates any

financial statements filed pursuant to the Securities Act or Exchange Act for any period from two years prior to the Original Issue Date

through the date this Note is no longer outstanding, and if the VWAP on the Trading Day following public announcement of such restatement

is 20% or more below the VWAP on the prior Trading Day (for announcements made before 4:00 p.m. New York time, the “next Trading

Day” means either the day of announcement or the following Trading Day); or

(xxi) the Company or a Subsidiary

enters into a Variable Rate Transaction or similar transaction prohibited under the Purchase Agreement without the prior written consent

of the Holder of this Note.

(b) Remedies Upon Event

of Default. Upon the delivery of a Default Declaration by the Holder of this Note in accordance with Section 5(a), the outstanding

principal amount of this Note, plus all accrued interest, liquidated damages and other amounts owing hereunder, shall become, at the election

of the Holder of this Note, immediately due and payable in cash at the Mandatory Default Amount; provided that if the Company’s

Common Stock is listed on a national securities exchange at the time of such Event of Default, the Mandatory Default Amount shall be reduced

to 100%. The Company hereby waives presentment, demand, protest and all other notices of any kind in connection with such acceleration.

Such acceleration may be rescinded by the Holder of this Note at any time prior to payment, without prejudice to any subsequent Event

of Default.

Upon Event of Default. Commencing upon the delivery of a Default Declaration and until such Event of Default is cured or waived by

the Holder of this Note, this Note shall accrue interest at an interest rate equal to the Default Interest Rate.

(d) Notice of Potential

Default. Upon learning of any event described in Section 5(a)(i) through (xxi) with respect to this Note, the Company shall within

two Trading Days deliver written notice thereof via facsimile or electronic mail and overnight courier (with next day delivery specified)

to the Holder of this Note.

Section 6. Miscellaneous.

(a) Notices.

All notices, offers, acceptance and any other acts under this Note (except payment) shall be in writing, and shall be sufficiently given

if delivered to the addressees in person, email, followed by FedEx or similar receipted next day delivery, as follows:

If to the Company:

Change Agents

Corporation

4400 Route 9 South, Suite 3100

Freehold, NJ 07728

Email: sam@changeagentscorp.com

Attention: Sam Knipper

with a copy to:

(which shall not constitute notice)

Sheppard Mullin Richter & Hampton

30 Rockefeller Plaza, 38th

Floor

New York, NY 10112

Email: rafriedman@sheppard.com

Attention: Richard Friedman

If to the Holder: To the address designated for such Holder

on the Issuance Schedule to the Purchase Agreement.

or to such other address as any of them, by notice to the other may

designate from time to time. Time shall be counted to, or from, as the case may be, the date of delivery.

(b) Absolute Obligation.

Except as expressly provided herein, no provision of this Note shall alter or impair the obligation of the Company, which is absolute

and unconditional, to pay the principal of, liquidated damages and accrued interest and late fees, as applicable, on this Note at the

time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation of the Company.

Note. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver, in exchange and substitution

for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen or destroyed Note, a new Note for the

principal amount of this Note so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction

of this Note, and of the ownership hereof, reasonably satisfactory to the Company.

(d) Exclusive Jurisdiction;

Governing Law; Prevailing Party Attorneys’ Fees. All questions concerning the construction, validity, enforcement and interpretation

of this Note and venue shall be governed by and construed and enforced in accordance with Section 6(a) of the Purchase Agreement. If any

party shall commence an Action or Proceeding to enforce or otherwise relating to this Note, then, in addition to the other obligations

of the Company elsewhere in this Note, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party

for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of

such Action or Proceeding.

(e) Waiver. Any

waiver by the Company or the Holder of this Note of a breach of any provision of this Note shall not operate as or be construed to be

a waiver of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Company or the

Holder of this Note to insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver

or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Note on any other

occasion. Any waiver by the Company or the Holder of this Note must be in writing.

(f) Severability. If

any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect. If any interest or other

amount due hereunder violates applicable usury law, the applicable rate shall automatically be reduced to the maximum permitted rate.

The Company waives the benefit of any stay, extension or usury law that would prohibit or forgive payment of any portion of the principal

or interest on this Note.

(g) Remedies and Injunctive

Relief. All remedies under this Note and the Transaction Documents are cumulative and in addition to any remedies at law or in equity.

The Company acknowledges that a breach of its obligations hereunder will cause irreparable harm to the Holder and agrees that the Holder

shall be entitled to injunctive relief without the necessity of showing economic loss or posting any bond. The Company shall provide all

information and documentation reasonably requested by the Holder to confirm the Company’s compliance with this Note.

(h) Next Trading Day.

Whenever any payment or other obligation hereunder shall be due on a day other than a Trading Day, such payment shall be made on the next

succeeding Trading Day.

(i) Headings. The headings

contained herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit or affect any of the

provisions hereof.

IN WITNESS WHEREOF, the Company

has caused this Note to be duly executed by a duly authorized officer as of the date first above indicated.

CHANGE AGENTS CORPORATION

By:

Name:

Sam Knipper

Title:

Chief Financial Officer

EX-4.2 — FORM OF SEPTEMBER 2026 PRE-FUNDED WARRANT

EX-4.2

Filename: ea030536101ex4-2.htm · Sequence: 3

Exhibit 4.2

NEITHER

THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION

OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES

ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES

ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT

AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE

SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY

MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

PRE-FUNDED COMMON STOCK PURCHASE WARRANT

CHANGE AGENTS CORPORATION

Warrant Shares: ___________

Original Issuance Date: September 8, 2026

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”)

certifies that, for value received, _____________, a Delaware limited partnership

(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter

set forth, at any time on or after September 8, 2026 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New

York, NY time) on a date which is five years from the Original Issuance Date (the “Termination Date”) but not thereafter,

to subscribe for and purchase from CHANGE AGENTS CORPORATION, a Delaware corporation or its assigns (the “Company”),

up to _______ shares of Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase

price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions.

Capitalized words and terms used and not otherwise defined herein and which are not otherwise descriptive shall have the meanings set

forth in that certain Note Purchase Agreement (the “Purchase Agreement”), dated September 8, 2026 by and between the

Company and the Holder.

Section 2. Exercise.

(a) Exercise

of Warrant. Exercise of this Warrant may be made, in whole or in part, at any time on or after the Initial Exercise Date and on or

before the Termination Date by delivery to the Company of a duly executed Notice of Exercise in the form attached as Exhibit A

(the “Notice of Exercise”). Within two Trading Days following exercise, the Holder shall deliver the aggregate Exercise

Price by wire transfer unless the cashless exercise procedure in Section 2(c) is specified. No ink-original Notice of Exercise or medallion

guarantee shall be required. The Holder shall not be required to physically surrender this Warrant until exercised in full, in which case

surrender shall occur within three Trading Days of the final Notice of Exercise. Partial exercises shall reduce the outstanding number

of Warrant Shares purchasable hereunder. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased

and the dates of purchase. The Company shall deliver any objection to any Notice of Exercise within two Business Days of receipt; failure

to timely object shall be deemed acceptance. By acceptance of this Warrant, the Holder acknowledges that, following partial exercise,

the number of Warrant Shares available for purchase may be less than the amount stated on the face hereof.

(b) Exercise

Price. The aggregate exercise price of this Warrant, except for a nominal

exercise price of $0.0001 per Warrant Share (the “Exercise Price”), was pre-funded to the Company on or prior to the

Initial Exercise Date. No additional consideration (other than the Exercise Price) shall be required to effect any exercise. The Holder

shall not be entitled to a refund of any portion of the pre-paid exercise price. The remaining unpaid exercise price per share shall be

0.0001.

Exercise. This Warrant may also be exercised by means of a “cashless exercise” in which the Holder shall receive a number

of Warrant Shares equal to [(A-B) × (X)] ÷ (A), where:

(A) = (i) the VWAP on the Trading Day

immediately preceding the Notice of Exercise if delivered on a non-Trading Day or before regular trading hours, (ii) at the Holder’s

option, either (y) the VWAP on the preceding Trading Day or (z) the Bid Price at the time of execution if the Notice of Exercise is executed

during regular trading hours and delivered within two hours thereafter, or (iii) the VWAP on the date of the Notice of Exercise if delivered

after the close of regular trading hours on a Trading Day;

(B) = the Exercise Price of this Warrant,

as adjusted hereunder; and

(X) = the number of Warrant Shares that

would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash

exercise rather than a cashless exercise.

If Warrant Shares are issued

in a cashless exercise, the parties acknowledge that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall

take on the characteristics of the Warrants being exercised, and the holding period of the Warrants may be tacked to the holding period

of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).

“Bid Price”

means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock are then listed

or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on such Trading

Market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. to 4:02 p.m. (New York, N.Y. time)), (b) if the Common Stock

are traded on OTCQB or OTCQX, the volume weighted average sales price of the Common Stock for such date (or the nearest preceding date)

on OTCQB or OTCQX as applicable, (c) if the Common Stock are not then listed or quoted for trading on OTCQB or OTCQX and if prices for

the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or

agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in

all other cases, the fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder

and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

“VWAP” means,

for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock are then listed or quoted

on The New York Stock Exchange, the NYSE American or any tier of The Nasdaq Stock Market (each,

a “Trading Market”), the daily volume weighted average price of the Common Stock for such date (or the nearest

preceding date) on such Trading Market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. to 4:02 p.m. (New York, N.Y.

time)), (b) if the Common Stock are traded on OTCQB or OTCQX, the volume weighted average sales price of the Common Stock for such date

(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock are not then listed or quoted for trading on

OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc.

(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common

Stock so reported, or (d) in all other cases, the fair market value of the Common Stock as determined by an independent appraiser selected

in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

Notwithstanding anything contained

herein to the contrary, subject to the Beneficial Ownership Limitation and the Conversion Limitation, on the Termination Date, this Warrant

shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

(d) Mechanics

of Exercise.

(i) Delivery

of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Company’s

share transfer agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s or its designee’s

balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if

the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of

the Warrant Shares to or resale of the Warrant Shares by Holder, or (B) if there is no effective registration statement and the Warrant

is exercised via cashless exercise at a time when such Warrant Shares would be eligible for resale under Rule 144 by a non-affiliate of

the Company, such Warrant Shares are delivered to Holder’s broker, and the Company receives a statement from Holder’s broker

that it has received instructions to sell the Warrant Shares or that it would take responsibility that the sales of the Warrant Shares

will only be made if the Warrant Shares are eligible to be sold under Rule 144, and otherwise by physical delivery of a certificate, registered

in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder

is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest

of (i) three Trading Days after the delivery to the Company of the Notice of Exercise or (ii) one Trading Day after delivery of the aggregate

Exercise Price to the Company (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise,

the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which

this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise

Price (other than in the case of a cashless exercise) is received within three Trading Days following delivery of the Notice of Exercise.

If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery

Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject

to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing

to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant

Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to use commercially reasonable

efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.

(ii) Delivery

of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the Holder’s request

and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing

the rights of the Holder to purchase the unpurchased Warrant Shares, which new Warrant shall in all other respects be identical with this

Warrant.

(iii) Rescission

Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)

by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

(iv) Compensation

for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if

the Company fails to deliver the Warrant Shares by the Warrant Share Delivery Date, and if the Holder is required by its broker to purchase

Common Stock in the open market to cover a sale of the Warrant Shares which the Holder anticipated receiving (a “Buy-In”),

then the Company shall (A) pay in cash to the Holder the amount by which the Holder’s total purchase price (including brokerage

commissions) exceeds the product of the number of undelivered Warrant Shares multiplied by the price at which the Holder’s sell

order was executed, and (B) at the Holder’s option, either reinstate the undelivered portion of the Warrant (in which case such

exercise shall be deemed rescinded) or deliver the number of Warrant Shares that would have been issued had the Company timely complied.

The Holder shall provide written notice of amounts payable and, upon Company request, evidence of such loss. Nothing herein limits the

Holder’s right to pursue other remedies at law or in equity, including specific performance.

(v) No

Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this

Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,

at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the

Exercise Price or round up to the next whole share.

(vi) Charges,

Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental

expense, all of which shall be paid by the Company. If Warrant Shares are to be issued in a name other than the Holder’s, this Warrant

when surrendered for exercise shall be accompanied by the Assignment Form attached as Exhibit B duly executed by the Holder, and

the Company may require payment of any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees for same-day processing

of any Notice of Exercise and all DTC fees for same-day electronic delivery of the Warrant Shares.

(vii) Closing

of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant,

pursuant to the terms hereof.

(e) Holder’s

Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise

any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise

as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting

as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)),

would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the

number of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Common

Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Common

Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder

or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted portion of any other

securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or

exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.

Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance

with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that

the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder

is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this

Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together

with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the

Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable

(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this

Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify

or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined

in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section

2(e), in determining the number of outstanding Common Stock, a Holder may rely on the number of outstanding Common Stock as reflected

in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public

announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Common

Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing

to the Holder the number of Common Stock then outstanding. In any case, the number of outstanding Common Stock shall be determined after

giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution

Parties since the date as of which such number of outstanding Common Stock was reported. The “Beneficial Ownership Limitation”

shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of Common Stock

issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation

provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of

the Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon exercise of this Warrant held by the

Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be

effective until the 61st day after such notice is delivered to the Company. The provisions

of this Section 2(e) shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section

2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation

herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations

contained in this paragraph shall apply to a successor holder of this Warrant. Notwithstanding anything in this Warrant to the contrary,

and in addition to the limitations set forth herein, if Company has not obtained Stockholder Approval, the Company shall not issue a number

of Warrant Shares, which when aggregated with all other securities that are required to be aggregated for purposes of Nasdaq Listing Rule

5635(d), would exceed 19.99% of the shares of Common Stock outstanding as of the date of definitive agreement with respect to the first

of such aggregated transactions (the “Conversion Limitation”). For purposes of this section, “Stockholder Approval”

means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity)

from the stockholders of the Company with respect to the issuance of the Warrant Shares hereunder that, when taken together with any other

securities that are required to be aggregated with the issuance of the Warrant Shares issued hereunder for purposes of Nasdaq Listing

Rule 5635(d), would exceed 19.99% of the issued and outstanding common stock as of the date of definitive agreement with respect to the

first of such aggregated transactions.

Section 3. Certain

Adjustments.

(a) Stock

Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes

a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in Common Stock

(which, for avoidance of doubt, shall not include any Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides

outstanding Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Common Stock

into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company,

then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Common Stock (excluding

treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Common Stock outstanding

immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that

the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective

immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become

effective immediately after the effective date in the case of a subdivision, combination or re-classification.

(b) Subsequent

Rights Offerings. If the Company grants, issues, or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities,

or other property pro rata to holders of Common Stock (other than to employees, consultants, or management) (“Purchase Rights”),

then the Holder will be entitled to acquire the aggregate Purchase Rights which the Holder could have acquired if it had held the number

of shares acquirable upon complete exercise of this Warrant (disregarding the Beneficial Ownership Limitation) immediately before the

record date for such Purchase Rights; provided that to the extent participation would cause the Holder to exceed the Beneficial Ownership

Limitation, such Purchase Rights shall be held in abeyance until participation would not result in exceeding the limitation.

Rata Distributions. If the Company declares or makes any dividend or other distribution of assets (or rights to acquire assets) to

holders of Common Stock, other than cash (including any distribution of stock, securities, property, or options by way of dividend, spin-off,

reclassification, or similar transaction) (a “Distribution”), the Holder shall be entitled to participate to the same

extent as if it had held the number of shares acquirable upon complete exercise of this Warrant (disregarding the Beneficial Ownership

Limitation) immediately before the record date for such Distribution; provided that to the extent participation would cause the Holder

to exceed the Beneficial Ownership Limitation, the portion of such Distribution shall be held in abeyance until participation would not

result in exceeding the limitation.

(d) Fundamental

Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions

effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any

sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series

of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another

Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,

cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,

in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory

share exchange pursuant to which the Common Stock are effectively converted into or exchanged for other securities, cash or property,

or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other

business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another

Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Common Stock (not including any

Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or

party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),

then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have

been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without

regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of common equity of the successor or acquiring

corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)

receivable as a result of such Fundamental Transaction by a holder of the number of Common Stock for which this Warrant is exercisable

immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).

For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate

Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,

and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value

of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash

or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration

it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in

a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all

of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements

in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental

Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity

evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding

number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Common Stock acquirable and receivable

upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,

and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative

value of the Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares

of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the

consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence

of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of

such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company”

shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations

of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named

as the Company herein.

(e) Calculations.

All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes

of this Section 3, the number of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of

Common Stock (excluding treasury shares, if any) issued and outstanding.

(f) Notice

to Holder

(i) Adjustment

to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly

deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment

to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

(ii) Notice

to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common

Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall

authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock

of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification

of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of

the assets of the Company, or any compulsory share exchange whereby the Common Stock are converted into other securities, cash or property,

or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,

then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email

address as it shall appear upon the Warrant Register (as defined below), at least 10 calendar days prior to the applicable record or effective

date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,

redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be

entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,

consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected

that holders of the Common Stock of record shall be entitled to exchange their Common Stock for securities, cash or other property deliverable

upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice

or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such

notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the

Company, the Company shall simultaneously file such notice with the Commission pursuant to a Form 8-K. The Holder shall remain entitled

to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice

except as may otherwise be expressly set forth herein.

Section 4. Transfer of Warrant.

(a) Transferability.

Subject to compliance with applicable securities laws and the conditions in Section 4(d), this Warrant and all rights hereunder (including

any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company

together with a written assignment substantially in the form attached hereto and funds sufficient to pay any transfer taxes. Upon such

surrender and payment, the Company shall execute and deliver a new Warrant in the name of the assignee in the denominations specified,

and shall issue to the assignor a new Warrant evidencing the portion not so assigned. The Holder shall not be required to physically surrender

this Warrant unless assigned in full, in which case surrender shall occur within five Trading Days of delivering the assignment form.

A properly assigned Warrant may be exercised by a new holder without having a new Warrant issued.

(b) New

Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,

together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or

its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,

the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance

with such notice. All Warrants issued on transfers or exchanges shall be dated the Original Issuance Date of this Warrant and shall be

identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant

Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder

of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other

purposes, absent actual notice to the contrary.

(d) Representation

by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise

hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or

reselling such Warrant or Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law,

except pursuant to sales registered or exempted under the Securities Act.

Section 5. Reserved.

Section 6. Miscellaneous.

(a) No

Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as

a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.

(b) Loss,

Theft, Destruction, or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft,

destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction,

of indemnity or security reasonably satisfactory to it (which shall not require the posting of any bond), and upon surrender and cancellation

of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor

and dated as of such cancellation, in lieu of such Warrant or stock certificate.

Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted

herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

(d) Authorized

Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued

Common Stock such number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this.

The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the

duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such

reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable

law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that

all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise and payment

in accordance herewith, be duly authorized, validly issued, fully paid and non-assessable and free from all taxes, liens, and charges

created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such

issue).

Except as waived or consented

to by the Holder, the Company shall not by any action (including amending its charter documents, or through any reorganization, transfer

of assets, consolidation, merger, dissolution, or issuance of securities) avoid or seek to avoid the observance or performance of any

terms of this Warrant, but will at all times in good faith assist in carrying out such terms and taking such actions as may be necessary

to protect the rights of Holder. The Company will (i) not increase the par value of any Warrant Shares above the Exercise Price, (ii)

take all action necessary to validly issue fully paid and non-assessable Warrant Shares upon exercise, and (iii) use commercially reasonable

efforts to obtain all authorizations, exemptions, or consents from any regulatory body necessary to perform its obligations under this

Warrant.

Before taking any action which

would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company

shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or

bodies having jurisdiction thereof.

(e) Governing

Law; Exclusive Jurisdiction. The provisions in the Purchase Agreement relating to governing law and exclusive jurisdiction are incorporated

from the Purchase Agreement and apply in all cases.

(f) Restrictions.

The Holder acknowledges that Warrant Shares acquired upon exercise, if not registered and the Holder does not utilize cashless exercise,

will have restrictions upon resale imposed by securities laws.

(g) Non-waiver

and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as

a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. If the Company willfully and knowingly fails

to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder

such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including

those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of

its rights, powers or remedies hereunder.

(h) Notices.

Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in

accordance with the notice provisions of the Purchase Agreement.

(i) Limitation

of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant

Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase

price of any Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the

Company.

(j) Remedies.

The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific

performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss

incurred by reason of a breach by it of the provisions of this Warrant and hereby waives the defense in any action for specific performance

that a remedy at law would be adequate.

(k) Successors

and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the

benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.

The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable

by the Holder or holder of Warrant Shares.

(l) Amendment.

This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

(m) Severability.

Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,

but if any provision shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such

prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Warrant.

(n) Headings.

The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company

has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

CHANGE AGENTS CORPORATION

By:

Name:

Sam Knipper

Title:

Chief Financial Officer

EXHIBIT A

NOTICE OF EXERCISE

TO: CHANGE AGENTS CORPORATION

(1) The undersigned hereby elects

to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders

herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form

of (check applicable box):

☐ in lawful money of the United States;

☐ if permitted the cancellation of

such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with

respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

(3) Please issue said Warrant

Shares in the name of the undersigned or in such other name as is specified below:

______________________

The Warrant Shares shall be delivered to the following

DWAC Account Number:

______________________

[SIGNATURE OF HOLDER]

Name of Investing Entity: _________________________________________________________

Signature of Authorized Signatory of Investing

Entity: __________________________________

Name of Authorized Signatory: ____________________________________________________

Title of Authorized Signatory: _____________________________________________________

Date: _________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this

form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and

all rights evidenced thereby are hereby assigned to

Name:

(Please Print)

Address:

Phone Number:

(Please Print)

Email Address:

Dated: ___________ __, _____

Holder’s Signature:

Holder’s Address:

Warrant Exercise Log

Date

Number of Warrant

Shares Available to be

Exercised

Number of Warrant Shares

Exercised

Number of

Warrant Shares

Remaining to be Exercised

EX-4.3 — FORM OF WAIVER PRE-FUNDED WARRANT

EX-4.3

Filename: ea030536101ex4-3.htm · Sequence: 4

Exhibit 4.3

NEITHER THIS SECURITY NOR THE SECURITIES

AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION

OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),

AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT

TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE

WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT. THIS SECURITY AND THE

SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED

BY SUCH SECURITIES.

PRE-FUNDED

COMMON STOCK PURCHASE WARRANT

CHANGE AGENTS CORPORATION

Warrant Shares: {50,000][34,000}

Date of Issuance: September __, 2026 (“Issuance

Date”)

This COMMON STOCK PURCHASE WARRANT (the “Warrant”)

certifies that, for value received, [Dune Equity Holdings LLC][FirstFire Global Opportunities Fund, LLC], a Delaware limited liability

company (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to

the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (the “Initial

Exercise Date”), to purchase from CHANGE AGENTS CORPORATION, a Delaware corporation (the “Company”), [50,000][34,000]

shares of Common Stock (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the

terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company to the Holder

as of the Issuance Date, pursuant to the waiver agreement entered into on the Issuance Date by and among the Company and the Holder (the

“Waiver”).

Capitalized terms

used in this Warrant shall have the meanings set forth in the Waiver unless otherwise defined in the body of this Warrant or in Section

16 below. For purposes of this Warrant, the term “Exercise Price” shall mean $0.0001, subject to adjustment as provided herein

(including but not limited to cashless exercise). “Exercise Period” shall mean the period commencing on the Initial Exercise

Date and ending on 5:00 p.m. eastern standard time on the date that is five (5) years after the Initial Exercise Date; provided, however,

that if (i) the Holder delivers the Buyout Notice (as defined in this Warrant) (the “Buyout Notice”) as set forth in this

Warrant and (ii) the Company pays the Buyout Amount (as defined in this Warrant) to the Holder in accordance with the terms of this Warrant,

then this Warrant shall be extinguished and redeemed in its entirety.

1. EXERCISE OF WARRANT.

(a) Mechanics

of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole or in part

at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit A (the

“Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder shall not be required to deliver

the original Warrant in order to effect an exercise hereunder. Partial exercises of this Warrant resulting in purchases of a portion of

the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable

hereunder in an amount equal to the applicable number of Warrant Shares purchased. On or before the second Trading Day (the “Warrant

Share Delivery Date”) following the date on which the Holder sent the Exercise Notice to the Company or the Company’s

transfer agent, and upon receipt by the Company of payment to the Company of an amount equal to the applicable Exercise Price multiplied

by the number of Warrant Shares as to which all or a portion of this Warrant is being exercised (the “Aggregate Exercise Price”

and together with the Exercise Notice, the “Exercise Delivery Documents”) in cash or by wire transfer of immediately

available funds (or by cashless exercise, in which case there shall be no Aggregate Exercise Price provided), the Company shall (or direct

its transfer agent to) issue and deliver by overnight courier to the address as specified in the Exercise Notice, a certificate, registered

in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the

Holder is entitled pursuant to such exercise (or deliver such shares of Common Stock in electronic format if requested by the Holder).

Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record

of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates

evidencing such Warrant Shares. If this Warrant is submitted in connection with any exercise and the number of Warrant Shares represented

by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company

shall as soon as practicable and in no event later than three Business Days after any exercise and at its own expense, issue a new Warrant

(in accordance with Section 7) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise

under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.

If the Company fails

to cause its transfer agent to issue to the Holder the respective shares of Common Stock by the respective Warrant Share Delivery Date,

then the Holder will have the right to rescind such exercise in Holder’s sole discretion in addition to all other rights and remedies

at law, under this Warrant, or otherwise.

If the Market Price

of one share of Common Stock is greater than the Exercise Price, then the Holder may elect to receive Warrant Shares pursuant to a cashless

exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described below (or of any portion thereof

remaining unexercised) by delivery of an Exercise Notice, in which event the Company shall issue to Holder a number of Common Stock computed

using the following formula:

X = Y (A-B)

Where

X = the number of Shares to be issued to Holder.

Y = the number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation).

A = the Market Price (at the date of such calculation).

B = Exercise Price (as adjusted to the date of such calculation).

(b) No

Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant

hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining

whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance

of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction

a sum in cash equal to the product resulting from multiplying the then-current fair market value of a Warrant Share by such fraction.

Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and a Holder shall

not have the right to exercise any portion of this Warrant, pursuant to Section 1 or otherwise, to the extent that after giving effect

to such issuance after exercise as set forth on the applicable Exercise Notice, the Holder (together with the Holder’s Affiliates),

and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution

Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing

sentence, the number of shares of Common Stock beneficially owned by the Holder and Attribution Parties shall include the number of shares

of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number

of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially

owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted

portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation

on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution

Parties. Except as set forth in the preceding sentence, for purposes of this Section 1(c), beneficial ownership shall be calculated in

accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder

that the Holder is solely responsible for any schedules required to be filed in accordance therewith. In addition, a determination as

to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations

promulgated thereunder. For purposes of this Section 1(c), in determining the number of outstanding shares of Common Stock, a Holder may

rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report

filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice

by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written

or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares

of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect

to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties

since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation”

shall be 4.99% of the number of shares of the Common Stock outstanding at the time of the respective calculation hereunder. Notwithstanding

anything in this Warrant to the contrary, the Company shall not issue a number of Common Stock pursuant to the exercise of this Warrant,

which when aggregated with all other securities that are required to be aggregated for purposes of Nasdaq Listing Rule 5635(d), would

exceed 19.99% of the shares of Common Stock outstanding as of the date of definitive agreement with respect to the first of such aggregated

transactions, unless the Company has obtained the Stockholder Approval (as defined in the Waiver) (the “Stockholder Approval”).

If the Company does not obtain Stockholder Approval at the first meeting of its shareholders after the Issuance Date, the Company shall

call a meeting every ninety (90) calendar days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder

Approval is obtained or this Warrant is no longer outstanding. If the Stockholder Approval is not obtained and deemed effective under

Delaware law on or before the date that is ninety (90) calendar days after the Issuance Date (the “Stockholder Approval Deadline

Date”), then the Holder shall have the right, exercisable upon written notice to the Company within seven (7) calendar days of the

Stockholder Approval Deadline Date (the “Buyout Notice”), to require the Company to pay [$125,000][$75,000.00] (the “Buyout

Amount”) in cash to the Holder within five (5) calendar days of the date of the Buyout Notice. If (i) the Holder delivers the Buyout

Notice pursuant to the immediately preceding sentence and (ii) the Company pays the Buyout Amount to the Holder within five (5) calendar

days of the date of the Buyout Notice, then this Warrant shall be extinguished and redeemed in the entirety. If (i) the Stockholder Approval

is obtained and deemed effective under Delaware law and (ii) the average of the closing prices of the Common Stock on the Principal Market

for the five (5) Trading Days immediately preceding the Stockholder Approval Date (the “True-Up Price”) is less than $2.50

per share (subject to adjustment for any stock dividend, stock split, stock combination, rights offerings, reclassification or similar

transaction that proportionately decreases or increases the number of outstanding Common Stock), then the Company shall pay True-Up Payment

(as defined in this Warrant) to the Holder within three (3) Trading Days of the Stockholder Approval Date. The “True-Up Payment”

shall mean [$125,000][$75,000.00] minus the Warrants Value (as defined in this Warrant). The “Warrants Value” shall mean the

total number of Exercise Shares underlying the Warrants on the Stockholder Approval Date multiplied by the True-Up Price. “Trading

Day” shall mean a day on which the Principal Market shall be open for business. The limitations contained in this paragraph shall

apply to a successor holder of this Warrant.

(d) Compensation

for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if

the Company fails to cause the Company’s transfer agent to deliver to the Holder the Warrant Shares in accordance with the provisions

of this Warrant (including but not limited to Section 1(a) above pursuant to an exercise on or before the respective Warrant Share Delivery

Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s

brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which

the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder, within

one (1) Business Day of Holder’s request, the amount, if any, by which (x) the Holder’s total purchase price (including brokerage

commissions, if any) for the shares of Common Stock so purchased exceeds (y) the product of (1) the number of Warrant Shares that the

Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving

rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent

number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to

the Holder within one (1) Business Day of Holder’s request the number of shares of Common Stock that would have been issued had

the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases, or effectuates

a cashless exercise hereunder for, Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted

exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of

the immediately preceding sentence, the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written

notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount

of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity

including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to

timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

2. ADJUSTMENTS.

The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as

set forth in this Section 2.

(a) Stock

Dividends and Splits. Without limiting any provision of Section 4, if the Company, at any time on or after the Issuance Date,

(i) pays a stock dividend on one or more classes of its then outstanding shares of Common Stock or otherwise makes a distribution on any

class of capital stock that is payable in shares of Common Stock, (ii) subdivides (by any stock split, stock dividend, recapitalization

or otherwise) one or more classes of its then outstanding shares of Common Stock into a larger number of shares or (iii) combines (by

combination, reverse stock split or otherwise) one or more classes of its then outstanding shares of Common Stock into a smaller number

of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares

of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding

immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the

record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause

(ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination. If any

event requiring an adjustment under this paragraph occurs during the period that an Exercise Price is calculated hereunder, then the calculation

of such Exercise Price shall be adjusted appropriately to reflect such event.

(b) [Reserved].

3. [Reserved].

4. PURCHASE

RIGHTS; FUNDAMENTAL TRANSACTIONS.

(a) [Reserved]

(b) Fundamental

Transactions. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity assumes in writing

all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 4(b) pursuant to written

agreements in form and substance satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including

agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument

substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number

of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard

to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the

exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant

to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number of shares of capital stock

and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of

such Fundamental Transaction). Upon the consummation of each Fundamental Transaction, the Successor Entity shall succeed to, and be substituted

for (so that from and after the date of the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction

Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power

of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the

same effect as if such Successor Entity had been named as the Company herein. Upon consummation of each Fundamental Transaction, the Successor

Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation

of the applicable Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property

issuable upon the exercise of this Warrant prior to the applicable Fundamental Transaction, such shares of publicly traded common stock

(or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the

happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction

(without regard to any limitations on the exercise of this Warrant), as adjusted in accordance with the provisions of this Warrant. Notwithstanding

the foregoing, and without limiting Section 1(c) hereof, the Holder may elect, at its sole option, by delivery of written notice to the

Company to waive this Section 4(b) to permit the Fundamental Transaction without the assumption of this Warrant. In addition to and

not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction pursuant to which holders

of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock

(a “Corporate Event”), the Company shall make appropriate provision to insure that the Holder will thereafter have the right

to receive upon an exercise of this Warrant at any time after the consummation of the applicable Fundamental Transaction but prior to

the Expiration Date, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property issuable upon the

exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever

(including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening

of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction

(without regard to any limitations on the exercise of this Warrant) (the “Corporate Event Consideration”). Provision made

pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holder.

(d) Application.

The provisions of this Section 4 shall apply similarly and equally to successive Fundamental Transactions and shall be applied as

if this Warrant (and any such subsequent warrants) were fully exercisable and without regard to any limitations on the exercise of this

Warrant (provided that the Holder shall continue to be entitled to the benefit of the Beneficial Ownership Limitation, applied however

with respect to shares of capital stock registered under the 1934 Act and thereafter receivable upon exercise of this Warrant (or any

such other warrant)).

5. NON-CIRCUMVENTION.

The Company covenants and agrees that it will not, by amendment of its articles of incorporation, bylaws or through any reorganization,

transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action,

avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out

all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality

of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this

Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the

Company may validly and legally issue fully paid and non-assessable shares of Common Stock upon the exercise of this Warrant, and (iii)

shall, for so long as this Warrant is outstanding, have authorized and reserved, free from preemptive rights, two (2) times the number

of shares of Common Stock into which the Warrants are then exercisable into to provide for the exercise of the rights represented by this

Warrant (without regard to any limitations on exercise).

6. WARRANT

HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder

of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose,

nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Warrant,

any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any

reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings,

receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled

to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities

on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such

liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide

the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously

with the giving thereof to the stockholders.

7. REISSUANCE.

(a) Lost,

Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to indemnity

or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new

Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

(b) Issuance

of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant shall

be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which is the same as

the Issuance Date.

8. TRANSFER.

This Warrant shall be binding upon the Company and its successors and assigns, and shall inure to be the benefit of the Holder and its

successors and assigns. Notwithstanding anything to the contrary herein, the rights, interests or obligations of the Company hereunder

may not be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior signed written consent of

the Holder, which consent may be withheld at the sole discretion of the Holder (any such assignment or transfer shall be null and void

if the Company does not obtain the prior signed written consent of the Holder). This Warrant or any of the severable rights and obligations

inuring to the benefit of or to be performed by Holder hereunder may be assigned by Holder to a third party, in whole or in part, without

the need to obtain the Company’s consent thereto.

9. NOTICES.

Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance

with the notice provisions contained in the First Note (as defined in the Waiver). The Company shall provide the Holder with prompt written

notice (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment

and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or

distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock or other securities directly

or indirectly convertible into or exercisable or exchangeable for shares of Common Stock or other property, pro rata to the holders of

shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation,

provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided

to the Holder.

10. DISCLOSURE.

Upon delivery by the Company to the Holder (or receipt by the Company from the Holder) of any notice in accordance with the terms of this

Warrant, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, non-public

information relating to the Company or any of its Subsidiaries, the Company shall on or prior to 9:00 am, New York city time on the Business

Day immediately following such notice delivery date, publicly disclose such material, non-public information on a Current Report on Form

8-K or otherwise. In the event that the Company believes that a notice contains material, non-public information relating to the Company

or any of its Subsidiaries, the Company so shall indicate to the Holder explicitly in writing in such notice (or immediately upon receipt

of notice from the Holder, as applicable), and in the absence of any such written indication in such notice (or notification from the

Company immediately upon receipt of notice from the Holder), the Holder shall be entitled to presume that information contained in the

notice does not constitute material, non-public information relating to the Company or any of its Subsidiaries. Nothing contained in this

Section 10 shall limit any obligations of the Company, or any rights of the Holder, under the Waiver.

11. ABSENCE

OF TRADING AND DISCLOSURE RESTRICTIONS. The Company acknowledges and agrees that the Holder is not a fiduciary or agent of the Company

and that the Holder shall have no obligation to (a) maintain the confidentiality of any information provided by the Company or (b) refrain

from trading any securities while in possession of such information in the absence of a written non-disclosure agreement signed by an

officer of the Holder that explicitly provides for such confidentiality and trading restrictions. In the absence of such an executed,

written non-disclosure agreement and subject to compliance with any applicable securities laws, the Company acknowledges that the Holder

may freely trade in any securities issued by the Company, may possess and use any information provided by the Company in connection with

such trading activity, and may disclose any such information to any third party.

12. AMENDMENT

AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively

or prospectively) only with the signed written consent of the Company and the Holder.

13. GOVERNING

LAW AND VENUE. Any action brought by either party against the other concerning the transactions contemplated by this Warrant shall

be brought only in the State of Delaware. This Warrant shall be construed and enforced in accordance with, and all questions concerning

the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of Delaware,

without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions)

that would cause the application of the laws of any jurisdictions other than the State of Delaware. For any litigation arising in connection

with this Warrant (and notwithstanding the terms (specifically including any governing law and venue terms) of any transfer agent services

agreement or other agreement between the Company’s transfer agent and the Company, such litigation specifically includes, without

limitation any action between or involving Company and the Company’s transfer agent with respect to this Warrant in any way (specifically

including, without limitation, any action where Company seeks to obtain an injunction, temporary restraining order, or otherwise prohibit

the Company’s transfer agent from issuing shares of Common Stock to Holder for any reason)), each party hereto hereby (i) consents

to and expressly submits to the exclusive personal jurisdiction of any state or federal court sitting in the State of Delaware, (ii) expressly

submits to the exclusive venue of any such court for the purposes hereof, (iii) agrees to not bring any such action (specifically including,

without limitation, any action where Company seeks to obtain an injunction, temporary restraining order, or otherwise prohibit the Company’s

transfer agent from issuing shares of Common Stock to Holder for any reason) outside of any state or federal court sitting in the State

of Delaware, and (iv) waives any claim of improper venue and any claim or objection that such courts are an inconvenient forum or any

other claim, defense or objection to the bringing of any such proceeding in such jurisdiction or to any claim that such venue of the suit,

action or proceeding is improper. Notwithstanding anything in the foregoing to the contrary, nothing herein (i) shall limit, or shall

be deemed or construed to limit, the ability of the Holder to realize on any collateral or any other security, or to enforce a judgment

or other court ruling in favor of the Holder, including through a legal action in any court of competent jurisdiction, or (ii) shall limit,

or shall be deemed or construed to limit, any provision of Section 15 of this Warrant. The Company hereby irrevocably waives, and agrees

not to assert in any suit, action or proceeding, any objection to jurisdiction and venue of any action instituted hereunder, any claim

that it is not personally subject to the jurisdiction of any such court, and any claim that such suit, action or proceeding is brought

in an inconvenient forum or that the venue of such suit, action or proceeding is improper (including but not limited to based upon forum

non conveniens). THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR

THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTIONS CONTEMPLATED HEREBY.

The Company irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding

in connection with this Warrant or any other agreement, certificate, instrument or document contemplated hereby or thereby by mailing

a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to the Company at the address in effect

for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof.

Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The prevailing

party in any action or dispute brought in connection with this Warrant or any other agreement, certificate, instrument or document contemplated

hereby or thereby shall be entitled to recover from the other party its reasonable attorney’s fees and costs. If any provision of

this Warrant shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity

or enforceability of the remainder of this Warrant in that jurisdiction or the validity or enforceability of any provision of this Warrant

in any other jurisdiction.

14. ACCEPTANCE.

Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained

herein.

15. DISPUTE

RESOLUTION.

(a) Submission

to Dispute Resolution.

(i) Notwithstanding

anything to the contrary in this Warrant, in the case of a dispute relating to the Exercise Price, the Closing Sale Price, the Closing

Bid Price, or fair market value or the arithmetic calculation of the number of Warrant Shares (as the case may be) (including, without

limitation, a dispute relating to the determination of any of the foregoing) (the “Warrant Calculations”), the Company or

the Holder (as the case may be) shall submit the dispute to the other party via electronic mail (A) if by the Company, within two (2)

Trading Days after the occurrence of the circumstances giving rise to such dispute or (B) if by the Holder, at any time after the Holder

learned of the circumstances giving rise to such dispute. If the Holder and the Company are unable to agree upon such determination or

calculation within two (2) Trading Days following such initial notice by the Company or the Holder (as the case may be) of such dispute

to the Company or the Holder (as the case may be), then the Holder may, at its sole option, submit the dispute to an independent, reputable

investment bank or independent, outside accountant selected by the Holder (the “Independent Third Party”), and the Company

shall pay all expenses of such Independent Third Party.

(ii) The

Holder and the Company shall each deliver to such Independent Third Party (A) a copy of the initial dispute submission so delivered in

accordance with the first sentence of this Section 15(a) and (B) written documentation supporting its position with respect to such dispute,

in each case, no later than 5:00 p.m. (New York time) by second (2nd) Business Day immediately following the date on which the Holder

selected such Independent Third Party (the “Dispute Submission Deadline”) (the documents referred to in the immediately preceding

clauses (A) and (B) are collectively referred to herein as the “Required Dispute Documentation”) (it being understood and

agreed that if either the Holder or the Company fails to so deliver all of the Required Dispute Documentation by the Dispute Submission

Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives

its right to) deliver or submit any written documentation or other support to such Independent Third Party with respect to such dispute

and such Independent Third Party shall resolve such dispute based solely on the Required Dispute Documentation that was delivered to such

Independent Third Party prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Company and the Holder

or otherwise requested by such Independent Third Party, neither the Company nor the Holder shall be entitled to deliver or submit any

written documentation or other support to such Independent Third Party in connection with such dispute, other than the Required Dispute

Documentation.

(iii) The

Company and the Holder shall cause such Independent Third Party to determine the resolution of such dispute and notify the Company and

the Holder of such resolution no later than five (5) Business Days immediately following the Dispute Submission Deadline. The fees and

expenses of such Independent Third Party shall be borne solely by the Company, and such Independent Third Party’s resolution of

such dispute shall be final and binding upon all parties absent manifest error.

(b) Miscellaneous.

The Company expressly acknowledges and agrees that (i) this Section 15 constitutes an agreement to arbitrate between the Company

and the Holder (and constitutes an arbitration agreement) under the rules then in effect under the Delaware Rules of Civil Procedure (“DRCP”)

and that the Holder is authorized to apply for an order to compel arbitration pursuant to the DRCP in order to compel compliance with

this Section 15, (ii) a dispute relating to the Warrant Calculations includes, without limitation, disputes as to (A) whether an

issuance or sale or deemed issuance or sale of Common Stock occurred under Section 2 of this Warrant, (B) the consideration per share

at which an issuance or deemed issuance of Common Stock occurred, and (C) whether any issuance or sale or deemed issuance or sale of Common

Stock was an issuance or sale or deemed issuance or sale, (iii) the terms of this Warrant and each other applicable Transaction Document

shall serve as the basis for the selected Independent Third Party’s resolution of the applicable dispute, such Independent Third

Party shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like that such Independent Third

Party determines are required to be made by such Independent Third Party in connection with its resolution of such dispute (including,

without limitation, determining (A) whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section 2 of

this Warrant, (B) the consideration per share at which an issuance or deemed issuance of Common Stock occurred, and (C) whether any issuance

or sale or deemed issuance or sale of Common Stock was an issuance or sale or deemed issuance or sale, and in resolving such dispute such

Independent Third Party shall apply such findings, determinations and the like to the terms of this Warrant and any other applicable Transaction

Documents, (iv) the Holder (and only the Holder), in its sole discretion, shall have the right to submit any dispute described in this

Section 15 to any other jurisdiction provided for in Section 13 of this Warrant in lieu of utilizing the procedures set forth in this

Section 15, and (v) nothing in this Section 15 shall limit the Holder from obtaining any injunctive relief or other equitable remedies

(including, without limitation, with respect to any matters described in this Section 15).

16. CERTAIN

DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

(a) “Affiliate”

means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control

with, such Person, it being understood for purposes of this definition that “control” of a Person means the power directly

or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct

or cause the direction of the management and policies of such Person whether by contract or otherwise.

(b) “Bloomberg”

means Bloomberg, L.P.

Day” means any day other than Saturday, Sunday or other day on which commercial banks in the State of Delaware are authorized

or required by law to remain closed; provided, however, for clarification, commercial

banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”,

“non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations

at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial

banks in the State of Delaware generally are open for use by customers on such day.

(d) “Change

of Control” means any Fundamental Transaction other than (i) any merger of the Company or any of its, direct or indirect, wholly-owned

Subsidiaries with or into any of the foregoing Persons, (ii) any reorganization, recapitalization or reclassification of the shares of

Common Stock in which holders of the Company’s voting power immediately prior to such reorganization, recapitalization or reclassification

continue after such reorganization, recapitalization or reclassification to hold publicly traded securities and, directly or indirectly,

are, in all material respects, the holders of the voting power of the surviving entity (or entities with the authority or voting power to

elect the members of the board of directors (or their equivalent if other than a corporation) of such entity or entities) after such reorganization,

recapitalization or reclassification, (iii) pursuant to a migratory merger effected solely for the purpose of changing the jurisdiction

of incorporation of the Company or any of its Subsidiaries or (iv) bone fide arm’s length acquisitions by the Company with one or

more third parties as long as holders of the Company’s voting power as of the Issuance Date continue after such acquisition to hold

publicly traded securities and, directly or indirectly, are, in all material respects, the holders of at least 51% of the voting power

of the surviving entity (or entities with the authority or voting power to elect the members of the board of directors (or their

equivalent if other than a corporation) of such entity or entities) after such acquisition.

(e) “Closing

Bid Price” and “Closing Sale Price” means, for any security as of any date, (i) the last closing bid price

and last closing trade price, respectively, for such security on the Principal Market, as reported by Quotestream or other similar quotation

service provider designated by the Holder, or, if the Principal Market begins to operate on an extended hours basis and does not designate

the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Quotestream or other

similar quotation service provider designated by the Holder, or (ii) if the foregoing does not apply, the last trade price of such security

in the over-the-counter market for such security as reported by Quotestream or other similar quotation service provider designated by

the Holder, or (iii) if no last trade price is reported for such security by Quotestream or other similar quotation service provider designated

by the Holder, the average of the bid and ask prices of any market makers for such security as reported by Quotestream or other similar

quotation service provider designated by the Holder. If the Closing Sale Price cannot be calculated for a security on a particular date

on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined

by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such

dispute shall be resolved in accordance with the procedures in Section 15. All such determinations to be appropriately adjusted for

any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

(f) “Common

Stock” means the common stock of the Company, $0.0001 par value per share, and any other class of securities into which such

securities may hereafter be reclassified or changed.

(g) “Common

Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock,

including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible

into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

(h) [Intentionally

Omitted].

(i) “Eligible

Market” means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, Nasdaq

Capital Market, or equivalent national securities exchange.

(j) [Intentionally

Omitted].

(k) [Intentionally

Omitted].

(l) [Intentionally

Omitted].

(m) “Fundamental

Transaction” means (A) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise,

in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another

Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of

the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation S-X) to one or more Subject Entities,

or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Stock be subject

to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either

(x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common

Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender

or exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Subject Entities making or party to,

or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial

owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock

or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off

or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire,

either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated

as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or

party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock

such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50%

of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its Common Stock, (B) that the Company shall,

directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject

Entity individually or the Subject Entities in the aggregate to be or become the “beneficial owner” (as defined in Rule 13d-3

under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange,

reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, spin-off,

scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least

50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock, (y) at least 50% of the aggregate ordinary

voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Warrant calculated

as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary

voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow

such Subject Entities to effect a statutory short form merger or other transaction requiring other shareholders of the Company to surrender

their shares of Common Stock without approval of the shareholders of the Company or (C) directly or indirectly, including through subsidiaries,

Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction

structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed

and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this

definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or

transaction.

(n) “Parent

Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent

equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent

Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

(o) “Person”

and “Persons” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust,

an unincorporated organization, any other entity and any governmental entity or any department or agency thereof.

(p) “Principal

Market” shall mean any of the national exchanges (i.e. NYSE, NYSE American, and Nasdaq) which

is at the time the principal trading platform for the Common Stock (excluding all OTC marketplaces).

(q) “Market

Price” means the highest traded price of the Common Stock during the thirty (30) Trading Days prior to the date of the respective

Exercise Notice.

(r) “Successor

Entity” means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental

Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been

entered into.

(s) “Trading

Day” means any day on which the Common Stock is listed or quoted on its Principal Market, provided, however, that if the Common

Stock is not then listed or quoted on any Principal Market, then any calendar day.

* * * * * * *

IN WITNESS WHEREOF, the Company has caused

this Warrant to be duly executed as of the Issuance Date set forth above.

CHANGE AGENTS CORPORATION

Name:

Sam Knipper

Title:

Chief Financial Officer

EXHIBIT A

EXERCISE NOTICE

(To be executed by the registered holder

to exercise this Common Stock Purchase Warrant)

THE

UNDERSIGNED holder hereby exercises the right to purchase of the shares of Common

Stock (“Warrant Shares”) of CHANGE AGENTS CORPORATION, a Delaware corporation (the “Company”), evidenced by the

attached copy of the Common Stock Purchase Warrant (the “Warrant”). Capitalized terms used herein and not otherwise defined

shall have the respective meanings set forth in the Warrant.

1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as (check one):

☐ a cash exercise with respect to Warrant Shares; or

☐ by cashless exercise pursuant to the Warrant.

2. Payment of Exercise Price. If cash exercise is selected above, the holder shall pay the applicable Aggregate Exercise Price

in the sum of $ to the Company in accordance with the terms of the Warrant.

3. Delivery of Warrant Shares. The Company shall deliver to the holder Warrant Shares in accordance with the terms

of the Warrant.

Date:

(Print Name of Registered Holder)

By:

Name:

Title:

EX-10.1 — FORM OF NOTE PURCHASE AGREEMENT

EX-10.1

Filename: ea030536101ex10-1.htm · Sequence: 5

Exhibit

10.1

NOTE

PURCHASE AGREEMENT

THIS

NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of September 8, 2026 (the “Execution Date”),

is entered into by and between CHANGE AGENTS CORPORATION, a Delaware corporation (the “Company”), and each

of the purchasers identified on the Issuance Schedule, including C/M Capital Master Fund, LP (collectively, the “Purchasers”

and each, a “Purchaser”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 7 below,

or as otherwise defined herein.

WHEREAS,

the Company and the Purchasers are executing and delivering this Agreement in reliance upon an exemption from securities registration

afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”)

under the Securities Act of 1933 (the “Securities Act”); and

WHEREAS,

each Purchaser desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement,

a promissory note of the Company, in the form attached hereto as Exhibit A, to each Purchaser in the respective principal amount

set forth opposite such Purchaser’s name on the Issuance Schedule attached hereto (each such note, together with any note

issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, a “Note”

and collectively, the “Notes”); and

WHEREAS,

as an inducement to enter into this Agreement, the Company has agreed to issue to the Purchasers, in connection with the applicable

Closing or Closings, pre-funded warrants to purchase 100,000 shares of Common Stock (the “Commitment Pre-Funded Warrants”)

allocated among the Purchasers pro rata based on their respective funding amounts as set forth on the Issuance Schedule, with the aggregate

number of Commitment Shares issued to all Purchasers in connection with all Closings provided further that the issuance of the Commitment

Shares under the pre-funded warrant will be in compliance with Nasdaq shareholder approval rules..

NOW

THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the

receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows:

1. PURCHASE

AND SALE OF NOTES.

(a)

Closing. On each applicable Closing Date (as defined below), the Company shall sell and issue to each Purchaser, and each Purchaser

shall purchase, its respective Note in the principal amount and for the funding amount set forth opposite such Purchaser’s name

on the Issuance Schedule (each such purchase and sale, a “Closing” and collectively, the “Closings”).

The funding amount for each Purchaser shall be as set forth on the Issuance Schedule (each, a “Company Funding Amount”

and collectively, the “Company Funding Amounts”). The date on which each Purchaser funds its Note shall be the “Funding

Date” applicable to such Purchaser.

(b)

Closing Date. The date of the issuance and sale of each Note constituting a Closing pursuant to this Agreement (each, a “Closing

Date”) shall be the date set forth opposite the applicable Purchaser’s name on the Issuance Schedule; provided

that, if no date is specified, such Closing Date shall be as soon as practicable after the Execution Date. The Closing Dates may be simultaneous

or occur on different dates, in each case as set forth on the Issuance Schedule.

(c)

Form of Payment. On the applicable Funding Date, each Purchaser shall deliver its respective funding amount by wire transfer of

immediately available funds, in accordance with the Company’s written wiring instructions.

2. REPRESENTATIONS

AND WARRANTIES OF THE PURCHASERS. Each Purchaser, severally and not jointly, represents

and warrants to the Company, solely as to itself, that:

(a)

Authorization; Enforcement. This Agreement has been duly and validly authorized by such Purchaser. This Agreement has been duly

executed and delivered on behalf of such Purchaser, and this Agreement constitutes a valid and binding agreement of such Purchaser enforceable

in accordance with its terms.

(b)

Accredited Investor Status. Such Purchaser is (i) an “accredited investor” as that term is defined in Rule 501 of

the General Rules and Regulations under the Securities Act by reason of Rule 501(a)(3) (an “Accredited Investor”),

(ii) experienced in making investments of the kind described in this Agreement and the related documents, (iii) able, by reason of the

business and financial experience of its officers (if an entity) and professional advisors (who are not affiliated with or compensated

in any way by the Company or any of its Affiliates or selling agents), to protect its own interests in connection with the transactions

described in this Agreement, and the related documents, and (iv) able to afford the entire loss of its investment in its Note.

3. REPRESENTATIONS

AND WARRANTIES OF THE COMPANY. The Company represents and warrants to each Purchaser

that as of the Execution Date and as of the applicable Closing Date and as of the applicable

Funding Date (or as of such other time expressly specified below):

(a)

Corporate Governance Compliance:

(i)

Issuance of Note. Each Note has been duly authorized and is being validly issued to the applicable Purchaser.

(ii)

Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and perform its obligations

under this Agreement and the other Transaction Documents. The execution and delivery of this Agreement and the other Transaction Documents

by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary

corporate action, and no further consent or authorization of the Company or its Board of Directors is required. Each of this Agreement

and the other Transaction Documents has been duly executed and delivered by the Company and constitutes a valid and binding obligation

of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable

bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies

or by other equitable principles of general application.

(iii)

No Conflicts. Except as set forth on Schedule 3(a)(iii), the execution, delivery and performance of this Agreement and the other

Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby will not

(a) result in a violation of the Company’s or any Subsidiary’s certificate or articles of incorporation, by-laws or other

organizational or charter documents, (b) conflict with, or constitute a material default of, any agreement, indenture, instrument or

any “lock-up” or similar provision of any underwriting or similar agreement to which the Company or any Subsidiary is a party,

or (c) result in a violation of any federal, state or local law, rule, regulation, order, judgment or decree (including federal and state

securities laws and regulations) applicable to the Company or any Subsidiary.

(b)

SEC and Offering Compliance:

(i)

Brokers. Except as set forth on Schedule 3(b)(i), no broker or finder is entitled to a commission or fee payable by the Company

or for which any Purchaser could become liable in connection with the transactions contemplated by this Agreement, and the Company has

taken no action which would give rise to any claim by any person for brokerage commissions, finder’s fees, transaction fees or

similar payments relating to this Agreement or the transactions contemplated hereby. Any and all fees due to any brokers or finders shall

be paid and satisfied solely by the Company at or prior to the applicable Closing, and the Company shall indemnify and hold harmless

each Purchaser from any claims by any broker or finder claiming a right to payment based on any agreement or arrangement with the Company.

(ii)

Regulation D Compliance. With respect to the Notes to be offered and sold hereunder, and subject to and in reliance on the Purchasers’

representations and warranties made in Section 2, the Company will satisfy all of the applicable requirements of compliance with Rule

506 under the Securities Act.

(iii)

Transfer Taxes. On the applicable Closing Date, all transfer or other taxes (other than income or similar taxes) which are required

to be paid in connection with the sale and transfer of the Notes to be sold to the Purchasers hereunder will be, or will have been, fully

paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

(iv)

SEC Reports; Financial Statements. Except as set forth on Schedule 3(b)(iv), the Company has timely filed all reports, schedules,

forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant

to Section 13(a) or 15(d) thereof, for the year preceding the date hereof (or such shorter period as the Company was required by law

or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference

therein, being collectively referred to herein as the “SEC Reports”). As of their respective dates, the SEC Reports

complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC

Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein

or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The

financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements

and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been

prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved

(“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited

financial statements may not contain all footnotes required by GAAP, and fairly present in all respects the financial position of the

Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods

then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

(v)

Absence of Certain Changes. Since the date of the latest financial statements included within the SEC Reports, there has been

no material adverse change in the business, properties, operations, financial condition or results of operations of the Company or its

Subsidiaries, taken as a whole.

(vi)

Breach of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties set

forth in this Section 3 in any material respect, and in addition to any other remedies available to any Purchaser pursuant to

this Agreement, it will be considered an “Event of Default” under the applicable Note only if such breach is not cured within

10 Business Days after written notice from any Purchaser.

4. GENERAL

COVENANTS.

(a)

Use of Proceeds. Except as set forth on Schedule 4(a), the Company shall use the net proceeds from the sale of the Notes for general

working capital and other general corporate purposes (which may include, without limitation, strategic investments and/or transactions)

and for the satisfaction of outstanding debt, provided however, such proceeds shall not be used for the redemption of any Common Stock

or Common Stock Equivalents or for the settlement of any outstanding litigation.

(b)

Indemnification. Each party (an “Indemnifying Party”) agrees to indemnify and hold harmless each other party, its

officers, directors, employees, authorized agents, and any controlling Person within the meaning of Section 15 of the Securities Act

or Section 20 of the Exchange Act from and against any Damages resulting from any misrepresentation, breach of warranty, or failure to

perform any covenant or agreement by the Indemnifying Party under this Agreement; provided that the obligations of the Purchasers under

this Section 4(b) are several and not joint, and no Purchaser shall be liable for any act or omission of any other Purchaser.

(c)

Certain Expenses and Fees. The Company shall pay all taxes and duties levied in connection with the delivery of the Notes to the

Purchasers. In addition, the Lead Investor shall have the right, in its sole discretion, to withhold $2,500 from the Lead Investor’s

Company Funding Amount and remit such amount directly to the Lead Investor’s legal counsel as payment toward the Lead Investor’s

legal fees and disbursements incurred in connection with this Agreement and the other Transaction Documents. Such withholding shall be

non-accountable, and the Lead Investor shall have no obligation to provide the Company with any accounting, invoices, receipts, or other

documentation regarding the application of such funds. Any amount so withheld shall be deemed paid by the Company for all purposes under

this Agreement.

5. SPECIAL

COVENANTS.

(a)

Prohibition on MCA Debt. While any portion of any Note remains outstanding, the Company shall not borrow or draw funds under any

merchant cash advance or similar cash flow–based financing arrangement.

(b)

Filing of Current Report. The Company agrees that it shall, within the time required under the Exchange Act, file with the SEC

a report on Form 8-K relating to the transactions contemplated by, and describing the material terms and conditions of, this Agreement

(the “Current Report”).

(c)

Commitment Pre-Funded Warrants. Upon the applicable Closing or Closings, the Company shall issue to the Purchasers (or their respective

designees) one or more pre-funded warrants (the “Pre-Funded Warrants”) to purchase, allocated pro rata among the Purchasers,

a number of shares of Common Stock equal in the aggregate to 100,000 (such shares, the “Pre-Funded Warrant Shares”), at an

exercise price of $0.0001 per share, in the form attached hereto as Exhibit B. Each Pre-Funded Warrant shall be subject

to a beneficial ownership limitation of 4.99% of the Company’s outstanding Common Stock (calculated in accordance with Section

13(d) of the Exchange Act). Upon delivery of written notice to the Company, each Purchaser may increase (effective on the 61st day following

such notice) or decrease such limitation to any percentage not exceeding 9.99%. Notwithstanding anything in this Agreement to the contrary,

and in addition to the limitations set forth herein, if Company has not obtained Stockholder Approval, the Company shall not issue a

number of Pre-Funded Warrant Shares, which when aggregated with all other securities that are required to be aggregated for purposes

of Nasdaq Listing Rule 5635(d), would exceed 19.99% of the shares of Common Stock outstanding as of the date of definitive agreement

with respect to the first of such aggregated transactions (the “Conversion Limitation”). For purposes of this section, “Stockholder

Approval” means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any

successor entity) from the stockholders of the Company with respect to the issuance of the Pre-Funded Warrant Shares under the Pre-Funded

Warrants that, when taken together with any other securities that are required to be aggregated with the issuance of the Pre-Funded Warrant

Shares issued under this P for purposes of Nasdaq Listing Rule 5635(d), would exceed 19.99% of the issued and outstanding common stock

as of the date of definitive agreement with respect to the first of such aggregated transactions.

(d)

Most Favored Nation. If at any time while any portion of any Note remains outstanding, the Company issues any non-convertible

debt to any third party on terms that are, taken as a whole, more favorable to such third party than those granted to any Purchaser under

this Agreement or the applicable Note (including, without limitation, with respect to interest rate, maturity, original issue discount,

security, covenants, or fees) (a “Subsequent Financing”), the Company shall provide written notice thereof to each Purchaser

within five Trading Days of the closing of such Subsequent Financing, together with a description of the material terms thereof. Each

Purchaser shall have 10 Trading Days following receipt of such notice to elect, independently by written notice to the Company, to amend

the terms of this Agreement and such Purchaser’s Note to incorporate any or all of such more favorable terms, which amendments

shall be deemed effective as of the closing date of such Subsequent Financing. An election by one Purchaser shall not bind any other

Purchaser. The foregoing shall not apply to (i) issuances of Common Stock or Common Stock Equivalents to employees, officers, directors,

or consultants of the Company pursuant to any equity incentive plan duly adopted by the Company’s Board of Directors; (ii) securities

issued in a firm-commitment underwritten registered public offering; (iii) securities issued in connection with a bona fide strategic

transaction approved by the Company’s Board of Directors where the primary purpose of such transaction is not the raising of capital;

or (iv) the Commitment Shares issued pursuant to Section 5(c).

(e)

Prohibition on Debt. From and after the applicable Closing Date, the Company shall not, and shall not permit any Subsidiary to,

directly or indirectly, incur, assume, guarantee, or otherwise become liable for any Indebtedness (including, without limitation, merchant

cash advances, convertible notes, promissory notes, and similar instruments) without the prior written consent of the Majority Holders,

except for: (i) trade payables incurred in the ordinary course of business consistent with past practice; (ii) Indebtedness existing

as of the applicable Closing Date and disclosed on Schedule 5(e) hereto; (iii) equipment financing and capital lease obligations not

exceeding $100,000 in the aggregate at any time outstanding; (iv) Indebtedness in an net increase amount of up to $250,000 and (v) any

Indebtedness issued to any Purchaser (or its designees).

(f)

Roll-Over Right. If at any time while any portion of any Note remains outstanding, or upon the occurrence of any future debt or

equity financing by the Company (a “Future Financing”), each Purchaser shall have an independent right, exercisable at such

Purchaser’s sole election, by delivery of written notice to the Company (a “Roll-Over Notice”), to apply all or any

portion of the then-outstanding principal amount of such Purchaser’s Note, together with all accrued and unpaid interest thereon

(the “Roll-Over Amount”), toward the purchase of securities offered in such Future Financing, on the same terms and conditions

as are offered to other purchasers in such Future Financing. Upon the Company’s receipt of a Roll-Over Notice from a Purchaser:

(i) such Purchaser’s Note shall be deemed repaid and cancelled to the extent of the Roll-Over Amount, and the Company’s obligation

to pay the Roll-Over Amount in cash shall be discharged; (ii) the Roll-Over Amount shall simultaneously be applied as purchase consideration

for the securities offered in the Future Financing, and such Purchaser shall be entitled to receive such securities as if it were a cash

purchaser in such amount; and (iii) if the Roll-Over Amount is less than the entire outstanding principal and accrued interest of such

Purchaser’s Note, such Note shall continue in effect with respect to the remaining balance. For the avoidance of doubt, the exercise

of the Roll-Over Right under this Section 5(f) shall constitute a repayment and cancellation of the applicable portion of such Purchaser’s

Note followed by a simultaneous new investment by such Purchaser in the Future Financing, and shall not constitute or be deemed to be

a “conversion” of such Note into equity or any other security. Such Purchaser’s participation in the Future Financing

pursuant to this Section shall be documented through the applicable purchase agreement or subscription documents for such Future Financing,

and such Purchaser shall execute such documents on the same terms as other purchasers therein. The Company shall provide each Purchaser

with written notice of any proposed Future Financing (a “Financing Notice”) not less than 10 Trading Days prior to the anticipated

closing thereof, including a description of the material terms of such Future Financing. Each Purchaser shall have 10 Trading Days following

receipt of the Financing Notice to deliver a Roll-Over Notice. If a Purchaser does not deliver a Roll-Over Notice within such period,

such Purchaser shall be deemed to have waived its Roll-Over Right with respect to such Future Financing (but shall retain its Roll-Over

Right with respect to any subsequent Future Financing). The Company shall not consummate any Future Financing without first complying

with the notice provisions of this Section, unless each Purchaser entitled to receive notice hereunder has waived such notice in writing.

(g)

Prohibition on Variable Rate Transactions. From and after the applicable Closing Date until April __, 2027, the Company shall

not, and shall not permit any Subsidiary to, directly or indirectly, enter into, assume, guarantee, or otherwise become a party to any

Variable Rate Transaction without the prior written consent of the Majority Holders. A violation of this Section shall constitute an

immediate Event of Default under the applicable Note without the requirement of any notice or cure period.

(h)

Reservation of Common Stock. Within five Business Days following the applicable Closing, the Company shall reserve and keep available

out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Pre-Funded Warrants,

a number of shares of Common Stock equal to 100% of the maximum number of shares of Common Stock then issuable upon exercise in full

of all outstanding Pre-Funded Warrants held by the Purchaser (without regard to any exercise limitations set forth therein, including

the Beneficial Ownership Limitation and the Conversion Limitation) (the “Required Reserve Amount”). The Company shall

at all times thereafter maintain reserved shares in an amount not less than the Required Reserve Amount, as adjusted from time to time

to reflect adjustments to the number of shares issuable upon exercise of the Pre-Funded Warrants in accordance with their terms. If at

any time the number of authorized and unissued shares of Common Stock available for reservation is insufficient to satisfy the Required

Reserve Amount, the Company shall promptly take all corporate action necessary to increase the Company’s authorized shares of Common

Stock to an amount sufficient to permit the reservation and issuance of the Required Reserve Amount, including, without limitation, calling

a special meeting of stockholders or soliciting written consents for such purpose within 60 calendar days of such insufficiency. Any

failure by the Company to comply with this Section 5(h) that remains uncured for 10 Business Days after written notice from any Purchaser

shall constitute an Event of Default under each affected Note. For the avoidance of doubt, the “Required Reserve Amount”

shall include the pre-funded warrants previously issued to the Purchaser on or about August 14, 2026.

(i)

Reservation Letter. Within two Business Days following the Company’s compliance with Section 5(h), the Company shall deliver

to each Purchaser a letter from the Company’s transfer agent (the “Reservation Letter”), in form and substance satisfactory

to such Purchaser, confirming that the Transfer Agent has reserved a number of shares of Common Stock equal to the Required Reserve Amount.

The Reservation Letter shall specify the aggregate number of shares so reserved and confirm that such shares are authorized, unissued

and free from any prior reservation or commitment. The Company shall deliver an updated Reservation Letter to each Purchaser promptly,

and in any event within five Business Days, following any adjustment to the Required Reserve Amount. Any failure by the Company to deliver

the Reservation Letter or any updated Reservation Letter as required by this Section 5(i) that remains uncured for 10 Business Days after

written notice from any Purchaser shall constitute an Event of Default under each affected Note.

(j)

Breach of Covenants. Any material breach by the Company of any covenant in Section 4, this Section 5, or elsewhere in this Agreement

that remains uncured for 10 Business Days after written notice from any Purchaser shall constitute an Event of Default under each affected

Note.

6. GOVERNING

LAW; MISCELLANEOUS.

(a)

Governing Law/Jurisdiction/Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of

Delaware without regard to principles of conflicts of laws. Each party hereby irrevocably submits that any dispute, controversy or claim

arising out of or relating to this Agreement, shall be submitted to the exclusive jurisdiction of the state courts of the State of Delaware

and the United States District Court for the District of Delaware. The parties to this Agreement hereby irrevocably waive any objection

to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue

or based upon forum non conveniens. The prevailing party shall be entitled to recover from the non-prevailing party its reasonable attorney’s

fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid

or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may

conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid

or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby

irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with

this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail or overnight delivery (with

evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall

constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any

right to serve process in any other manner permitted by law.

(b)

JURY TRIAL WAIVER. THE COMPANY AND EACH PURCHASER HEREBY WAIVE A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT

BY ANY PARTY HERETO AGAINST ANY OTHER PARTY HERETO IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THE TRANSACTION DOCUMENTS.

(c)

Counterparts; Signatures by Electronic Mail. This Agreement may be executed in one or more counterparts, each of which shall be

deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been

signed by each party and delivered to the other parties. This Agreement, once executed by a party, may be delivered to the other parties

hereto by electronic mail transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

(d)

Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation

of, this Agreement.

(e)

Severability. In the event that any provision of this Agreement or of any of the Transaction Documents is invalid or unenforceable

under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith

and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable

under any law shall not affect the validity or enforceability of any other provision hereof.

(f)

Entire Agreement; Amendments. This Agreement and the instruments referenced herein, and the Transaction Documents, contain the

entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein

or therein, neither the Company nor any Purchaser makes any representation, warranty, covenant or undertaking with respect to such matters.

No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the Company and the Majority

Holders; provided, however, that no such waiver or amendment may, without the written consent of the Purchaser adversely affected thereby,

amend, waive, or otherwise adversely affect the economic rights of such Purchaser under its Note.

(g)

Notices. Any notices, consents, demands, requests, waivers or other communications required or permitted to be given under the

terms of this Agreement or the Notes must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally;

(ii) upon receipt, when sent by electronic mail (provided that such sent email is kept on file (whether electronically or otherwise)

by the sending party and the sending party does not receive an automatically generated message from the recipient’s email server

that such e-mail could not be delivered to such recipient; or (iii) one Trading Day after deposit with an overnight courier service with

next day delivery specified, in each case, properly addressed to the party to receive the same. The mailing addresses and e-mail addresses

for such communications shall be:

to the Company:

Change

Agents Corporation

4400

Route 9 South, Suite 3100

Freehold,

NJ 07728

Email:

sam@changeagentscorp.com

Attention:

Sam Knipper

With

a copy to (which shall not constitute notice or service of process):

Sheppard

Mullin Richter & Hampton

Rockefeller Plaza, 38th Floor

New

York, NY 10112

Email:

rafriedman@sheppard.com

Attention:

Richard Friedman

to any Purchaser: At the mailing address and e-mail address set forth opposite such Purchaser’s name on the Issuance Schedule

Any

party hereto may from time to time change its address or e-mail for notices under this Section 6(g) by giving at least 10 days’

prior written notice of such changed address to the other parties hereto.

(h)

Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and

assigns. Neither the Company nor any Purchaser shall assign this Agreement or any rights or obligations hereunder without the prior written

consent of the Company (in the case of an assignment by a Purchaser) or the affected Purchaser or Purchasers (in the case of an assignment

by the Company). Notwithstanding the foregoing, each Purchaser may independently assign its rights hereunder and under its Note to any

person that purchases such Purchaser’s Note in a private transaction from such Purchaser or to any of its “Affiliates,”

as that term is defined under the Exchange Act, without the consent of the Company or any other Purchaser.

(i)

Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto, the Purchasers and their respective

Affiliates, and their respective permitted successors and assigns and is not for the benefit of, nor may any provision hereof be enforced

by, any other Person.

(j)

Survival. The representations, warranties, agreements and covenants in this Agreement shall survive the Closings and the termination

or satisfaction of the Notes for the longest period allowable under applicable law. Each party agrees to indemnify and hold harmless

each other party and its officers, directors, employees and agents for any loss or damage arising from any breach by such party of its

representations, warranties, covenants or obligations under this Agreement, including advancement of expenses as incurred.

(k)

Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and

shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request

in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated

hereby.

(l)

No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express

their mutual intent, and no rules of strict construction will be applied against any party.

(m)

Remedies.

(i)

The Company acknowledges that a breach of its obligations hereunder will cause irreparable harm to each Purchaser. Accordingly, each

Purchaser shall be entitled to injunctive relief and specific performance without the necessity of showing economic loss or posting any

bond, in addition to all other remedies at law or in equity.

(ii)

The Company shall reimburse each Purchaser for all costs, fees, expenses and attorneys’ fees incurred in connection with any action

to enforce such Purchaser’s rights under this Agreement.

7. DEFINED

TERMS. As used in this Agreement, the following terms shall have the following meanings

specified or indicated (such meanings to be equally applicable to both the singular and plural

forms of the terms defined):

“Affiliate”

means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, or is

controlled by, or is under common control with, such Person, and the term “control” (including the terms “controlled

by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause

the direction of the management policies of such Person, whether through ownership of voting securities, by contract or otherwise.

“Common

Stock” means the common stock of the Company, par value $0.001 per share.

“Common

Stock Equivalent” means any securities of the Company entitling the holder thereof to acquire at any time Common Stock, including,

without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable

or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

“Damages”

shall mean any loss, claim, damage, liability, cost and expense (including, without limitation, reasonable attorneys’ fees and

disbursements and costs and expenses of expert witnesses and investigation).

“Exchange

Act” shall mean the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.

“Indebtedness”

means, with respect to any Person, without duplication, (a) all indebtedness of such Person for borrowed money, (b) all obligations of

such Person evidenced by bonds, debentures, notes, or other similar instruments, (c) all obligations of such Person in respect of letters

of credit, bankers’ acceptances, or other similar instruments (or reimbursement obligations with respect thereto), (d) all obligations

of such Person to pay the deferred purchase price of property or services (other than trade payables incurred in the ordinary course

of business), (e) all obligations of such Person as lessee under capital leases or finance leases, (f) all indebtedness of others secured

by a lien on any asset of such Person, whether or not such indebtedness is assumed by such Person, (g) all indebtedness of others guaranteed

by such Person, (h) all obligations of such Person under any merchant cash advance, revenue-based financing, or similar cash flow–based

financing arrangement, and (i) all obligations of such Person under any convertible notes, promissory notes, or similar debt instruments.

“Lead

Investor” means C/M Capital Master Fund, LP. The Lead Investor has no special rights, powers, or duties beyond those of any

other Purchaser under this Agreement, except as may be expressly set forth herein (and there are none).

“Majority

Holders” means the Purchasers holding Notes representing more than 50% of the aggregate outstanding principal amount of all

Notes then outstanding.

“Note”

means each promissory note of the Company issued to a Purchaser pursuant to this Agreement in the principal amount set forth opposite

such Purchaser’s name on the Issuance Schedule, together with any note issued in replacement thereof or as a dividend thereon or

otherwise with respect thereto in accordance with its terms, and “Notes” means all such notes collectively.

“Person”

means an individual, a corporation, a partnership, an association, a trust or other entity or organization, any other entity, including

a government or political subdivision or an agency or instrumentality thereof.

“Purchaser”

means each purchaser identified on the Issuance Schedule, and “Purchasers” means all such purchasers collectively.

“Subsidiary”

or “Subsidiaries” means any Person in which the Company, directly or indirectly, owns or controls more than 50% of

the outstanding voting securities or similar voting interests, or otherwise has the power to direct or cause the direction of the management

and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.

“Trading

Day” shall mean a day on which the Trading Market shall be open for business.

“Trading

Market” means the Nasdaq Stock Market.

“Transaction

Documents” shall mean this Agreement, the Notes, Pre-Funded Warrant, and all schedules, exhibits, and ancillary documents executed

and delivered in connection herewith or therewith.

“Variable

Rate Transaction” means any transaction, agreement, or arrangement pursuant to which the Company or any Subsidiary (a) issues

or sells any debt or equity securities that are convertible into, exchangeable for, or otherwise entitle the holder thereof to receive

additional shares of Common Stock or Common Stock Equivalents at a conversion, exercise, or exchange rate or price that is based upon

or varies with the trading price of the Common Stock or any other variable pricing mechanism, (b) enters into any interest rate swap,

floating rate note, adjustable-rate loan, or similar agreement or instrument in which the interest rate, payment amount, or other material

economic term is tied to a floating rate, benchmark rate (including SOFR, prime rate, or any successor benchmark), or other variable

measure, (c) enters into any merchant cash advance, revenue-based financing, or similar cash flow–based financing arrangement in

which the repayment amount, factor rate, or payment schedule varies based on the Company’s revenue, receivables, or other variable

performance metric, or (d) enters into any other financing, hedging, or similar arrangement that is substantially similar in structure

or economic effect to the foregoing. For the avoidance of doubt, “Variable Rate Transaction” shall include, without limitation,

equity lines of credit, at-the-market offerings with variable pricing, and any transaction in which the Company may issue securities

at a future-determined price based on a discount to market price or a formula tied to the trading price of the Common Stock.

Signature

Page Follows

WITNESS WHEREOF, the Purchasers and the Company have caused their respective signature pages to this Note Purchase Agreement to be

duly executed as of the Execution Date.

COMPANY:

CHANGE

AGENTS CORPORATION

By:

Name:

Sam Knipper

Title:

Chief Financial Officer

PURCHASERS:

C/M CAPITAL MASTER FUND, LP

By:

Name:

Thomas Walsh

Title:

General Partner

WVP Emerging

Manager Onshore Fund, LLC – C/M Capital Series

By:

Name:

Thomas Walsh

Title:

Manager

Signature

Page to Note Purchase Agreement

ISSUANCE

SCHEDULE

WVP

Emerging Manager Onshore Fund, LLC – C/M Capital Series

Funding

Amount: $45,455

Principal:

$50,909

1111

Brickell Avenue, Suite 2920

Miami,

FL 33131

C/M

Capital Master Fund, LP

Funding

Amount: $204,545

Principal:

$229,091

1111

Brickell Avenue, Suite 2920

Miami,

FL 33131

The funding amount shall be net $2,500 subject to the Company’s

reimbursement/direct payment at the Closing to for legal fees and transaction expenses incurred on behalf of the Purchasers as contemplated

by the Agreement.

EXHIBITS

EXHIBIT

A – FORM OF NOTE

EXHIBIT

B – FORM OF PRE-FUNDED WARRANT

EXHIBIT

FORM

OF NOTE

[Attached.]

Exhibit A

EX-10.2 — SECOND AMENDMENT TO EQUITY PURCHASE AGREEMENT DATED SEPTEMBER 9, 2026

EX-10.2

Filename: ea030536101ex10-2.htm · Sequence: 6

Exhibit 10.2

SECOND AMENDMENT TO THE

EQUITY PURCHASE AGREEMENT

This second

amendment (this “Amendment”) to the Agreement (as defined below) is entered into as of September 9, 2026 (the “Effective

Date”), by and between Change Agents Corporation, a Delaware corporation (the “Company”), and Hudson Global Ventures,

LLC, a Nevada limited liability company (the “Investor”, and collectively with the Company, the “Parties”).

WHEREAS the Parties

entered into an equity purchase agreement on or around July 22, 2026 (as amended from time to time, the “Agreement”), as well

as that first amendment to the Agreement on or around August 21, 2026; and

WHEREAS, the Parties

now desire to amend the Agreement;

NOW, THEREFORE,

the Parties hereto agree as follows:

1. Applicable Trading Amount. The definition of “Applicable Trading Amount” in Section

1.1 of the Agreement shall be replaced by the following:

“Applicable Trading

Amount” shall mean the following:

(a) $15,000.00 if (i) the VWAP of the Common Stock during the

period beginning at the start of regular trading hours” as defined in Rule 600(b)(88) of

Regulation NMS promulgated under the federal securities laws on the Put Date and continuing through the time of the delivery of the Put

Notice to Investor is greater than $2.50, and (ii) the total trading volume of the Company’s Common Stock on the Principal

Market on the Put Date prior to the delivery of the Put Notice to Investor exceeds 100,000 shares; or

(b) $15,000.00 if the lowest closing price of the Common Stock during

the two (2) Trading Days immediately preceding the respective Put Date is greater than $3.00 but less than or equal to $3.50; or

the two (2) Trading Days immediately preceding the respective Put Date is greater than $3.50 but less than or equal to $4.00; or

(d) $100,000.00 if the lowest closing price of the Common Stock during

the two (2) Trading Days immediately preceding the respective Put Date is greater than $4.00 but less than or equal to $5.00; or

(e) $200,000.00 if the lowest closing price of the Common Stock during

the two (2) Trading Days immediately preceding the respective Put Date is greater than $5.00 but less than or equal to $6.50; or

(f) $350,000.00 if the lowest closing price of the Common Stock during

the two (2) Trading Days immediately preceding the respective Put Date is greater than $6.50 but less than or equal to $9.00; or

(g) $450,000.00 if the lowest closing price of the Common Stock during

the two (2) Trading Days immediately preceding the respective Put Date is greater than $9.00 but less than or equal to $15.00; or

(h) $500,000.00 if the lowest closing price of the Common Stock

during the two (2) Trading Days immediately preceding the respective Put Date is greater than $15.00.

For the avoidance of doubt, each

of the closing prices as well as the number of shares identified above in this definition of Applicable Trading Amount are subject to

adjustment for any stock dividend, stock split, stock combination, rights offerings, reclassification or similar transaction that proportionately

decreases or increases the number of outstanding Common Stock. Notwithstanding the foregoing, if the parameters in any of the subsections

(b) through (h) of the definition of Applicable Trading Amount are satisfied on the respective Put Date, then subsection (a) of the definition

of Applicable Trading Amount shall not apply on the respective Put Date.

2. Purchase Price. The reference to “$0.20” in the definition of Purchase Price in Section

1.1 of the Agreement shall be replaced with “$2.00”.

3. Minimum Pricing. The reference to “equal or exceed $0.30 per share” in Section 7.2(o)

of the Agreement shall be replaced with “exceed 3.00 per share”. The following sentence also shall be added to Section 7.2(o)

of the Agreement: “This Section 7.2(o) of the Agreement shall not apply to a Put Notice that is being delivered pursuant to the

parameters in subsection (a) of the definition of Applicable Trading Amount.”

4. Shareholder Approval. The reference to “seventy-five (75) calendar days” in Section

6.2 of the Agreement shall be replaced with “ninety (90) calendar days”.

5. Effect of Amendment; Full Force and Effect. This Amendment shall form a part of the Agreement for

all purposes, and each Party shall be bound hereby and this Amendment and the Agreement shall be read and interpreted as one combined

instrument. From and after the date hereof, each reference in the Agreement to “this Agreement,” “hereof,” “hereunder,”

“herein,” “hereby” or words of like import referring to the Agreement shall mean and be a reference to the Agreement

as amended by this Amendment. Except as herein expressly amended or otherwise provided herein, each and every term, condition, warranty

and provision of the Agreement shall remain in full force and effect, and such are hereby ratified, confirmed and approved by the Parties.

6. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be

deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature

page to this Amendment by electronic means, including DocuSign, Adobe Sign or other similar e-signature services, e-mail or scanned pages

shall be effective as delivery of a manually executed counterpart to this Amendment.

[Signature Page Follows]

WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed by their respective officers thereunto duly authorized

as of the Effective Date.

COMPANY:

CHANGE AGENTS CORPORATION

By:

Name:

Sam Knipper

Title:

Chief Financial Officer

INVESTOR:

HUDSON GLOBAL VENTURES, LLC

By:

Name:

Seth Ahdoot

Title:

Member

EX-10.3 — FORM OF SEPTEMBER 2026 WAIVER

EX-10.3

Filename: ea030536101ex10-3.htm · Sequence: 7

Exhibit 10.3

WAIVER AGREEMENT

This waiver agreement (this “Waiver”)

is entered into as of September __, 2026 (the “Effective Date”), by and between Change Agents Corporation, a Delaware corporation

(the “Company”), and [Dune Equity Holdings LLC][FirstFire Global Opportunities Fund, LLC], a Delaware limited liability company

(the “Holder”). Reference is made to those certain promissory notes, dated as of June 2, 2026 (the “First Note”)

and August 13, 2026 (the “Second Note”, and collectively with the First Note, the Notes”), each in the original principal

amount of $250,000.00, issued by the Company to the Holder. Capitalized terms used but not defined herein have the meanings given in the

Notes. The Company and the Holder agree as follows:

1. Limited Waiver; Warrants.

a. Subject to the terms of this Waiver, the Holder hereby agrees to the following: [(i) the Amortization

Payment (as defined in the First Note) originally due on September 1, 2026, shall instead be due on the Maturity Date (as defined in the

First Note),] (ii) a one-time waiver of its rights under Section 1.3 of the Notes solely as it applies to (a) the promissory note in the

original principal amount of $229,091.00 (for which the Company received gross proceeds of $204,545.00), which was issued by the Company

to C/M Capital Master Fund, LP on or around September 8, 2026 (the “CM Note”) and (b) the promissory note in the original

principal amount of $50,909.00 (for which the Company received gross proceeds of $45,455.00), which was issued by the Company to WVP Emerging

Manager Onshore Fund, LLC on or around September 8, 2026 (the “WVP Note”, and collectively with the CM Note, the “CM

Notes”), and (iii) a one-time waiver of the repayment from proceeds under Section 1.4 of the Notes solely with respect to the proceeds

received by the Company pursuant to the CM Notes.

b. In consideration for the Holder’s execution of this Waiver, the Company shall issue to the Holder

a pre-funded warrant (the “Pre-Funded Warrant”) to purchase, [50,000][34,000] shares (the “Pre-Funded Warrant Shares”)

of Common Stock (as defined below), at an exercise price of $0.0001 per share, in the form attached hereto as Exhibit A. Notwithstanding

anything in this Agreement to the contrary, and in addition to the limitations set forth herein, the Company shall not issue a number

of Pre-Funded Warrant Shares, which when aggregated with all other securities that are required to be aggregated for purposes of Nasdaq

Listing Rule 5635(d), would exceed 19.99% of the shares of Common Stock outstanding as of the date of definitive agreement with respect

to the first of such aggregated transactions, unless the Company has obtained the Stockholder Approval (as defined below). “Common

Stock” shall mean the Company’s common stock, $0.0001 par value per share, and any shares of any other class of common stock whether

now or hereafter authorized, having the right to participate in the distribution of dividends (as and when declared) and assets (upon

liquidation of the Company).

c. “Stockholder Approval” means such approval as may be required by the applicable rules and

regulations of the Nasdaq Stock Market LLC (or any successor entity) from the stockholders of the Company with respect to the issuance

of Common Stock under the Warrants (the “Exercise Shares”) that, when taken together with any other securities that are required

to be aggregated with the issuance of the Exercise Shares for purposes of Nasdaq Listing Rule 5635(d), would exceed 19.99% of the issued

and outstanding Common Stock as of the date of definitive agreement with respect to the first of such aggregated transactions. The Company

shall use reasonable best efforts to obtain the Stockholder Approval at the first meeting of its shareholders after the Effective Date.

2. Full Force and Effect. Except as expressly

set forth herein, the Notes remains in full force and effect and are hereby ratified and confirmed.

3. Governing Law and Venue; Counterparts. Section

3.6 of the First Note shall apply to this Waiver. This Waiver may be executed in counterparts (including by electronic transmission),

each of which shall be deemed an original and all of which together shall constitute one instrument.

[Signature page to follow]

IN WITNESS WHEREOF, the parties have executed this

Waiver as of the date first written above.

CHANGE AGENTS CORPORATION

By:

Name:

Sam Knipper

Title:

Chief Financial Officer

[DUNE EQUITY HOLDINGS LLC][FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC]

By:

FirstFire Capital Management LLC, its manager

By:

Name:

Eli Fireman

Exhibit A

(see attached)

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 12

v3.26.3

Cover

Sep. 08, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 08, 2026

Entity File Number

001-38728

Entity Registrant Name

Change Agents Corporation

Entity Central Index Key

0001630212

Entity Tax Identification Number

47-1685128

Entity Incorporation, State or Country Code

Entity Address, Address Line One

4400 Route 9 South

Entity Address, Address Line Two

Suite 3100

Entity Address, City or Town

Freehold

Entity Address, State or Province

Entity Address, Postal Zip Code

07728

City Area Code

732

Local Phone Number

780-4400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.0001 par value

Trading Symbol

CHGA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration